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Several studies have reported poorer health outcomes especially lifestyle related diseases (e.g. 
cardiovascular diseases and type 2 diabetes mellitus [T2DM]) among indigenous peoples 
throughout the world. Rapid industrialisation of the societies with a more sedentary lifestyle 
and increased calorie intake, which have taken place to varying degrees among both 
indigenous and benchmark populations have been implicated in this regard. As well as the 
lifestyle related changes, the indigenous Sami people in Norway, like many other indigenous 
peoples throughout the world, experienced centuries of stigmatisation and assimilation 
policies. Both the lifestyle changes and experienced assimilation policies might give rise to 
increased vulnerability to somatic and psychological disorders. 
The present thesis aims to measure the prevalence and incidence of diabetes mellitus (DM) 
among Sami and non-Sami inhabitants of Northern Norway in order to explore ethnic 
difference and to elucidate any explanatory factor, which can account for the possible 
disparities.  
Paper 1 was based on data from a cross-sectional population-based survey, the SAMINOR 1 
Survey (2003–2004). A total of 27,151 individuals aged 36–79 years were invited and 15,208 
were included in the analysis. Self-report (questionnaire) and/or non-fasting/random plasma 
glucose (RPG) ≥11.1 mmol/L were used to define DM and 7.8 mmol/L ≤ RPG <11.1 mmol/L 
was used to define pre-diabetes. Age-standardised prevalence of pre-diabetes and DM among 
Sami men was respectively 3.4% and 5.5%. Corresponding values for non-Sami men were 
3.3% and 4.6%. Age-standardised prevalence of pre-diabetes and DM for Sami women was 
2.7% and 4.8%, respectively, while corresponding values for non-Sami women were 2.3% 
and 4.5%. However, no statistical significant ethnic difference was observed in the overall 
age-adjusted prevalence of pre-diabetes and DM. Nevertheless, the prevalence of DM was 
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higher among Sami in southern regions and lower in northern regions compared with their 
non-Sami counterparts.   
Paper 2 was based on data from another cross-sectional population-based survey, the 
SAMINOR 2 Clinical Survey (2012–2014). A total of 12,455 Sami and non-Sami inhabitants 
aged 40–79 years were invited to participate and 5878 were included in the analyses. Self-
reported T2DM and/or HbA1c ≥ 6.5% were applied to define T2DM and 5.7% ≤ HbA1c 
<6.5% to define pre-diabetes. In men, the total age-standardised prevalence of pre-diabetes 
(37.9% vs 31.4%) and T2DM (10.8% vs 9.5%) were higher in Sami compared with non-
Sami; the age-adjusted ethnic differences were statistically significant for both pre-diabetes 
(OR 1.42, 95% CI: 1.20–1.68) and T2DM (OR 1.31, 95% CI: 1.01–1.70). In women, pre-
diabetes (36.4% vs 33.5%) and T2DM (8.6% vs 7.0%) were also more prevalent in Sami than 
non-Sami; the age-adjusted differences in both pre-diabetes (OR 1.20, 95% CI: 1.02–1.41) 
and T2DM (OR 1.38, 95% CI: 1.05–1.82) were also statistically significant. The observed 
ethnic difference in the waist-to-height ratio (WHtR) was a plausible explanation for the 
ethnic difference in the prevalence of pre-diabetes and T2DM. 
The overall prevalence of pre-diabetes and DM was high among both Sami and non-Sami 
participants in both surveys. Although no ethnic difference was observed in the prevalence of 
pre-diabetes or DM in the SAMINOR 1 Survey (based on self-report and/or RPG ≥ 11.1 
mmol/L), the prevalence values were higher among Sami participants relative to their non-
Sami counterparts in the SAMINOR 2 Clinical Survey (based on self-report and/or HbA1c 
≥6.5%). Higher obesity indices (BMI, WHtR) could be plausible explanatory factors for the 
observed differences.   
Paper 3 was a longitudinal study, which followed participants in the SAMINOR 1 Survey to 
the SAMINOR 2 Clinical Survey. DM was defined based on self-report and/or HbA1c ≥6.5%. 
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The 8-year cumulative incidence of DM was calculated by dividing the number of incident 
DM cases by the number of DM-free participants in the SAMINOR 1 Survey. The 8-year 
cumulative incidence of DM was 6.1% (201 incident cases) with no statistically significant 
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Type 2 diabetes mellitus (T2DM) has evolved into an ever-increasing epidemic worldwide 
[1]. The disease is prevalent in both developed and developing countries, but the prevalence 
of the disease has been rising more rapidly in middle- and low-income countries [2]. T2DM is 
the major cause of blindness, renal failure, heart attacks, stroke and lower limb amputation in 
the world [2] and if no concerted efforts are made to address the risk factors, early diagnosis 
and treatment of the disease, the harmful microvascular and macrovascular complications of it 
will remain a major burden for decades to come [1]. Deficient action of insulin either due to 
inadequate insulin secretion or diminished tissue responses to insulin at one or more points in 
the complex pathway of hormone actions comprises the basis of T2DM [3]. Although genetic 
predisposition is a known risk factor for T2DM [4], many cases of T2DM can be prevented 
through lifestyle changes like increasing physical activity and restriction of calorie intake [2]. 
Adiposity is the most important risk factor for development of T2DM [5-7]. The protective 
effect of physical activity goes primarily through improved insulin sensitivity and glucose 
metabolism [8]. Although physical activity can play an important role in maintaining body 
weight and composition within normal ranges, a reduction in body weight is not necessary for 
the beneficial effect on glucose homeostasis [9].  
A newly conducted Norwegian nationwide cohort study linked data from national registries 
with prospectively collected data on DM medication and diagnoses for all Norwegian 
residents aged 30 to 89 years (>3.2 million people) [10]. According to this study, while the 
prevalence of T2DM increased from 4.9% in 2009 to 6.1% in 2014, during the same period, 
the incidence of the disease decreased significantly from 609 cases per 100,000 person-years 
to 398 cases per 100,000 (an annual reduction of 10.1%). This decline was seen for both 
pharmacologically and non-pharmacologically treated T2DM and was present in all sex, age, 
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education level and place of birth subgroups [10]. The authors concluded that the observed 
rise in the prevalence of T2DM despite decreasing incidence of the disease might be due to 
diagnosis at a younger age and increased longevity. In 2004, the prevalence of known cases of 
any type of DM in the age group ≥30 years in all Norway was estimated to 3.4% [11]. Nystad 
reported the prevalence of known cases of any type of DM in selected municipalities of 
Northern and Mid-Norway to be 4.0% in men and 4.1% in women in 2003–2004 [12]. At the 
same time, the prevalence of metabolic syndrome was quite high yet not significantly 
different between the Sami and non-Sami inhabitants of Northern and Mid-Norway [13]. In 
the period 1959–1975, mortality due to ischemic heart disease in Norway was highest in 
Finnmark county [14]. This prompted several cardiovascular surveys in this county. As 
cardiovascular disease and DM are risk factors for each other and share many risk factors 
[15], it can be expected that if the prevalence of cardiovascular disease is high in a region, the 
prevalence of DM might be high as well.  
The Sami people is an indigenous population who traditionally inhabited northern parts of 
Norway, Sweden, Finland and Kola Peninsula in Russia. They, in combination with other 
ethnic groups, comprise the heterogeneous population of Northern Norway with a large and 
longstanding interaction between the ethnic groups. The Sami people have experienced 
colonialism and have been victims of a state- and church-driven assimilation policy [16]. The 
pervasive assimilation policy brought about loss or extensive changes in traditional practices, 
languages, norms, and believes of the Sami people [17]. These changes in tandem with 
lifestyle changes due to rapid modernisation and industrialisation ensuing the Second World 
War, which affected all ethnic groups in the region, made the Sami people vulnerable and 
prone to lifestyle-related and chronic diseases like T2DM. Several studies have reported 
similar lifestyle trends with resultant higher incidence and prevalence of related diseases 
among other indigenous peoples throughout the world [18-26]. 
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The scarcity of knowledge about health and living conditions of the Sami people in Norway 
prompted the Centre for Sami Health Research to conduct the SAMINOR Study (the 
SAMINOR 1 Survey in 2003–2004 and the SAMINOR 2 Survey in 2012–2014). The study 
provided invaluable insight into various social, psychological, and somatic aspects of health 
and living of the inhabitants in the included municipalities. The main aim of the present thesis 
was to promote more knowledge about the incidence and prevalence of DM among Sami and 
non-Sami inhabitants of the included municipalities, some risk factors for T2DM and any 






1.1.1 Diabetes Mellitus 
Diabetes mellitus (DM) is a chronic progressive disease resulting from either insufficient 
insulin secretion or impairment in insulin action [2]. Incident cases of Type 1 diabetes 
mellitus (T1DM) are seen mainly in children and adolescents, but it can occur virtually at any 
age [3]. T2DM occurs predominantly in adults, but it affects increasingly adolescents and 
young adults [27].  
1.1.2 Pathophysiology of diabetes mellitus 
T1DM, which accounts for approximately 5–10% of DM cases [3], arises due to destruction 
of β-cells of the pancreas predominantly through an autoimmune process in over 95% of 
cases (type 1A) or idiopathic in less than 5% of cases (type 1B) [15]. If T1DM is left 
untreated it usually manifests itself as ketoacidosis [15]. The disease is a catabolic disorder 
with virtually absent circulating insulin, elevated plasma glucagon, and lack of pancreatic β-
cells response to all insulinogenic stimuli, necessitating use of exogenous insulin [15]. In 
immune-mediated T1DM, approximately one-third of the disease susceptibility is gene-
mediated and two-thirds is due to environmental factors [15]. In a mild form of autoimmune-
mediated T1DM, patients initially retain enough β-cells function to avoid ketosis, but as the 
disease progresses later in life, they also become dependent on exogenous insulin. It is been 
reported that in Northern European countries, up to 15% of T2DM cases may actually have 
this mild form of T1DM (latent autoimmune diabetes of adults; LADA) [15]. The fact that the 
prevalence of T1DM is higher in Scandinavian countries and increases by migration to 
Northern Hemisphere supports the involvement of environmental factors in the development 
of T1DM [15].  
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T2DM represents a heterogeneous group of conditions, where circulating endogenous insulin 
is usually adequate to prevent ketoacidosis, but insufficient to prevent hyperglycaemia in the 
presence of increased needs due to tissue insensitivity (insulin resistance) [15]. Insulin 
resistance may occur in tissues like skeletal muscles, adipose tissue and liver [28]. This, in 
turn, leads to compensatory increased secretion of insulin to overcome insulin resistance [29]. 
At first, compensatory hyperinsulinemia maintains plasma glucose levels within the normal 
range, but eventually with the gradual decline in the insulin production by β-cells of the 
pancreas, the person enters overt diabetic phase [30, 31]. Nonetheless, most of the times, 
impairment of insulin secretion and insulin resistance coexist in the same patient and it is 
unclear which abnormality, if either alone, is the primary pathology [3]. Genetic and 
environmental factors interplay to develop both the insulin resistance and the β-cell loss 
(Figure 1) [15]. Several epidemiologic studies have indicated strong genetic associations, 
since in monozygotic twins over 40 years of age, there is a 70% one-year concordance in the 
development of T2DM [15]. Numerous genetic loci have so far been implicated in heightened 
risk of T2DM, most of them appear to encode proteins involved in β-cell development and 











1.1.3 Signs, symptoms, and late complications of type 2 diabetes mellitus 
The majority of patients with T2DM (especially obese ones) have an insidious onset of 
hyperglycaemia and are asymptomatic initially [15]. Classic symptoms of T2DM include 
polyuria, polydipsia, unexplained weight loss, accompanied sometimes with polyphagia [3]. 
Complications of T2DM can be divided into microvascular and macrovascular complications. 
Microvascular complications include blurred vision due to retinopathy, numbness and tingling 
(paraesthesia) in the limbs (diabetic polyneuropathy), autonomic neuropathy and resultant 
gastrointestinal, genitourinary, and cardiovascular symptoms as well as sexual dysfunction [3, 
4, 32]. Macrovascular complications of T2DM include coronary artery disease, stroke, arterial 
insufficiency (necrotic ulcers in the lower extremities leading sometimes to amputation), 
mesenteric ischemia, and diabetic nephropathy [4].  
If the glycaemic state is poorly controlled, the patient may develop diabetic ketoacidosis or 
hyperglycaemic hyperosmolar coma [15].  
By diagnosing patients in early phase of the disease, the development of the disease can, in 
most cases, either be prevented or delayed so that late complications are avoided to the 




Figure 2. Late complications of diabetes mellitus. Source: Colourbox  
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1.1.4 Risk factors for type 2 diabetes mellitus 
Several risk factors have been mentioned in the literature for development of T2DM. 
Although the exact mechanism of action of all these risk factors are not completely known, it 
is highly likely that factors like advanced age, overweight (BMI ≥ 25 kg/m2) and obesity, low 
physical activity, and family history of T2DM have causal relationship to the development of 
T2DM. On the other hand, risk factors like hypertriglyceridemia, hypercholesterolemia, low 
HDL, hypertension, polycystic ovary syndrome, acanthosis nigricans, and history of 
cardiovascular disease might have only an association (non-causal relationship) with T2DM 
[15, 28, 33]. Male sex has been mentioned as a risk factor for undiagnosed diabetes, which 
might be a proxy for other unfortunate factors like abdominal obesity, smoking and lower 
willingness to seek medical care [34]. T2DM is more prevalent among African Americans, 
Latinos, Native Americans and some other ethnic groups, which might be due to a combined 
effect of genetic predisposition and environmental factors [4]. 
Discrimination has been reported to be associated with both obesity [35] and T2DM [36, 37]. 
There is a plethora of studies showing that early life events like child maltreatment, 
malnutrition, economic insecurity, low socioeconomic status, and even in-uterus exposure to 
gestational diabetes and maternal hyperglycaemia as contributors to the development of 
T2DM later in life [38-41]. On the other hand, it is been reported that breastfeeding was 
associated with reduced incidence of DM in mothers and offspring among indigenous people 
in Canada [42].  
Of the mentioned risk factors, obesity is the most important factor causing insulin resistance 
[15]. While visceral obesity, owing to accumulation of fat in the omental and mesenteric 
regions, is highly correlated with insulin resistance; subcutaneous abdominal fat has less of an 
association with insulin insensitivity [15]. It is believed that in obese people, adipose tissue 
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releases higher amounts of non-esterified fatty acids, glycerol, hormones, pro-inflammatory 
cytokines, and other factors contributing to development of insulin resistance [28, 43]. The 
prevalence of general obesity (BMI ≥ 30 kg/m2) was reported to be higher among participants 
who had Sami as their home language in three generations compared to Norwegian 
participants, both in men (26.9% vs 23.4%) and women (38.7% vs 24.3%) [44]. In the 
Finnmark study, BMI was reported to be the dominant risk factor for DM among men, while 
in women this association was less prominent. In both sexes a dose-response relationship 
between obesity and DM was observed [45]. 
High plasma triglycerides and low plasma HDL cholesterol have been shown to contribute to 
insulin resistance via increasing circulating levels of free fatty acids resulted from heightened 
insulin levels and enhanced chylomicron-assembly and secretion in the gut [46]. The strong 
observed association between hypertension and T2DM has been linked to insulin resistance 
[47], endothelial dysfunction [48], and inflammatory processes [49, 50] being present in both 
conditions. Smoking can increase the risk of T2DM through insulin resistance [51, 52] and 
inadequate compensatory insulin secretion response [53]. Physical activity has a well-known 
and strong protective effect against development of T2DM both directly by increasing insulin 
sensitivity [54] and indirectly by alteration in body mass and composition [55, 56]. 
Individuals of lower socioeconomic status (e.g. lower educated, unemployed) are at higher 
risk of developing T2DM and its complications [57-59]. Dietary habits have substantial 
impact on the development of T2DM [60]. Intake of foods with high glycaemic index was 
found to be an important risk factor for development of T2DM in numerous studies [61-63]. 
High consumption of sugar-sweetened beverages are strongly correlated with development of 
T2DM, particularly among children [64]. While regular consumption of white rice increased 
the risk of T2DM development, replacement of white rice with brown rice or other whole 
grains had a protective effect [65]. Higher intake of polyunsaturated fat and long-chain n.3 
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fatty acids was reported as being protective against development of T2DM, while higher 
intake of saturated fat and trans fat had adverse effect on glucose metabolism and insulin 
resistance [66]. Similarly, higher intake of butter, potato, and whole milk was reported to be 
associated with increased risk of development of T2DM, while higher consumption of fruits 
and vegetables was associated with lower risk of T2DM [67, 68]. The positive effect of plant-
based regimens on insulin sensitivity and decreasing risk of T2DM has been attributed to their 
rich fibre content [69].  
In Norway, Sami people live in both urban and rural areas in the inland or coastal regions and 
their diet, just like for other ethnic groups, differs from region to region. Furthermore, the 
dietary habits vary from generation to generation and from rural to urban settings [70]. As the 
T2DM is a chronic disease and its risk factors might have been present some years or decades 
before onset of the disease, it is challenging to attribute the development of T2DM to a 
specific kind of food eaten by a given ethnic group. In the inland regions, the consumption of 
reindeer is much higher among Sami people compared with non-Sami, while in the coastal 
regions this difference is less remarkable [71]. Interestingly, obesity is more prevalent in the 
inland regions where the reindeer consumption is highest [44, 72]. The higher intake of fat as 
spread on bread, total coffee, freshwater fish, reindeer meat, moose meat, and food made with 
animal blood and lower consumption of vegetables, potatoes, total fish, lean fish and chicken 
[71], might be an explanation for the higher prevalence of adiposity and consequently T2DM 





Pre-diabetes can be defined as impaired fasting glucose (IFG), impaired glucose tolerance test 
(IGT), or abnormal glycated haemoglobin (HbA1c) [74]. The term “pre-diabetes” implies a 
relatively high risk for future development of DM (although this is not always the case) [74]. 
The American Diabetes Association (ADA) stresses that IFG or IGT should not be regarded 
as clinical entities in their own right, but rather risk factors for T2DM as well as 
cardiovascular disease [3]. It has been reported that the incidence of T2DM among those with 
HbA1c levels at 6.0–6.4% is more than 10 times that of those with lower levels [75-78]. 
However, this HbA1c range fails to identify a substantial proportion of those who have IFG 
and/or IGT [3]. Prospective studies demonstrate that those with HbA1c range at 6.0–6.4% has 
a 5-year cumulative incidence of T2DM that ranges from 12 to 25% [75-78]. Data from the 
National Health and Nutrition Examination Survey (NHANES) indicate that among the 
nondiabetic adult population, a fasting plasma glucose (FPG) of 6.1 mmol/L corresponds to 
an HbA1c of 5.6% and an FPG of 5.6 mmol/L corresponds to an HbA1c of 5.4% [3].  
Some trials have reported that among those with a pre-diabetes state, lifestyle interventions 
may prevent or delay onset of T2DM [79]. The ADA recommends that those with pre-
diabetes state (especially those with HbA1c levels above 6.0%) being informed of their 
increased risk for T2DM and counselled about effective strategies such as weight reduction 




1.3 Diagnosis of pre-diabetes and diabetes mellitus 
T1DM is usually diagnosed based on its sufficiently characteristic clinical onset with 
relatively acute, extreme increases in glucose concentrations in the face of characteristic 
symptoms, such that specific blood glucose cut-offs are not required for diagnosis in most 
clinical settings [80]. Diagnosis of T2DM can be made through one of the criteria which 
follows [3]: (Criteria 1 through 3 should be confirmed by repeat testing.) 
1) HbA1c ≥ 6.5% (48 mmol/L) 
2) Fasting plasma glucose (FPG) ≥ 7 mmol/L (126 mg/dL) 
3) 2-hour postprandial (2hpp) plasma glucose ≥ 11.1 mmol/L (200 mg/dL) after oral 
intake of 75g glucose  
4) Random plasma glucose (RPG) ≥ 11.1 mmol/L (200 mg/dL) in the presence of classic 
symptoms of hyperglycaemia or hyperglycaemic crisis 
In Norway, the HbA1c criterion is preferred for diagnosis of T2DM, and glucose 
measurements (fasting or oral glucose tolerance test [OGTT]) should be used if HbA1c is 
regarded inadequate [81, 82].  
There is internationally an inconsistency as how to define pre-diabetes to the extent that “a 
transatlantic trip may cure or cause pre-diabetes simply as a result of small but important 
differences in diagnostic criteria” [83]. According to the ADA diagnostic criteria, pre-diabetes 
is IFG (fasting glucose= 5.6–6.9 mmol/L), IGT (two-hour glucose levels on the 75-gram oral 
glucose tolerance test=7.8–11.0 mmol/L), or HbA1c 5.7–6.4% [3]. In 2003, the International 
Expert Committee defined pre-diabetes as IFG 5.6–6.9 mmol/L or IGT 7.8–11.0 mmol/L 
[84]. In this report, the committee did not recommend HbA1c as a diagnostic test for DM due 
to lack of standardised methodology. In 2009, however, the committee approved HbA1c as a 
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diagnostic test for DM, recommending HbA1c 6.0–6.4% as pre-diabetic range [80]. The 
World Health Organisation (WHO) recommends IFG 6.0–6.9 mmol/L or IGT 7.8–11.0 
mmol/L for categorising pre-diabetes [85]. It should be emphasised that as with the case with 
FPG and 2hpp, defining a lower cut-off for HbA1c to categorise pre-diabetes is somewhat 
arbitrary as the risk of T2DM with any measure or surrogate of glycaemia is a continuum, 





1.4 Non-fasting plasma glucose measurement 
As mentioned above, random (non-fasting) plasma glucose (RPG) measurement can 
(especially in emergencies) be applied to check hyperglycaemia at the presence of classic 
signs and/or symptoms of hyperglycaemia. In some studies, especially in the past when other 
glycaemic indicators like HbA1c or FPG were not standardised or feasible, RPG 
measurement was used to ascertain DM. There are, however, some shortcomings of using 
RPG in both screening measures and epidemiological studies. Primarily, the RPG levels are 
strongly influenced by the postprandial time and times of the day [86]. Furthermore, 
sensitivity of RPG at ≥ 11.1 mmol/L for detecting DM is quite low [86]. According to the 
study conducted by Ziemer et al. the sensitivity, specificity and positive predictive value 
(PPV) of RPG for diagnosing DM at cut-off 140 mg/dL (7.8 mmol/L) was 20%, 97% and 
26%, respectively (with the prevalence of DM around 5%) [86]. They did not present the 
sensitivity of the test at 11.1 mmol/l, but it is expected that higher cut-off of a test would yield 
even lower sensitivity. Based on these findings, Ziemer et al. suggested using RPG≥ 125 
mg/dL (6.9 mmol/L) (sensitivity=40% and specificity=93%) as an opportunistic initial 
screening test for patients at risk of glucose intolerance. Johnson et al. reported 63% 
sensitivity and 87% specificity with an RPG cut-off of 130 mg/dL (7.2 mmol/L) [87]. Zhang 
et al. found that a (non-fasting) capillary glucose of 120 mg/dL (6.6 mmol/L) would provide a 
89% specificity and 68% sensitivity [88]. The abovementioned studies used OGTT as the 
reference test. The common denominator for all these and numerous other studies is that the 
sensitivity of RPG measurement with cut-offs higher than 7.8 mmol/L for detecting 
undiagnosed DM is quite low. Perhaps the reason that only one RPG≥ 11.1 mmol/L (in the 
presence of classic signs and symptoms of DM) is sufficient for diagnosis of DM is the 
extremely high specificity and PPV of RPG measurement at this cut-off (albeit at the expense 
of extremely low sensitivity of the test).   
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1.5 Glycated haemoglobin  
HbA1c demonstrates the ratio between glycated HbA1 and total HbA1 and represents the 
average plasma glucose concentration during the preceding 2–3 months [81]. The 
concentration of HbA1c is determined by concentration of glucose in blood and erythrocyte 
lifespan [89]. HbA1c has been used as an important biomarker for glycaemia control in 
patients with DM since 1980’s [90]. In 2009, the International Expert Committee approved 
the diagnostic use of HbA1c in the wake of its standardisation [91]. In 2012, the Norwegian 
Directorate of Health approved and recommended HbA1c in the diagnosis of DM and stated 
that glucose measurements (fasting or OGTT) should be used when HbA1c is unreliable as a 
measure of the level of glycaemia such as in anaemia [82]. The ADA has recommended 
HbA1c ≥ 6.5% for diagnosing DM and 5.7 ≤  HbA1c < 6.5% for diagnosing pre-diabetes [3]. 
The diagnostic HbA1c cut-off levels were determined based on epidemiologic studies 
reflecting the strong association between HbA1c concentration and occurrence of retinopathy 
[3, 81, 92, 93]. HbA1c measurement has various advantages over glucose measurements like 
better sample stability, low intra-individual variation, independence of acute factors such as 
illness, recent food intake, stress, or exercise, and no need for prior fasting or glucose 
overload [94]. On the other hand, there are some conditions, which affect HbA1c values like 
iron deficiency anemia, chronic renal failure, pregnancy, and conditions causing shortened 
erythrocyte lifespan [95]. Beside these shortcomings of HbA1c, this test has been reported in 
several studies to be insensitive at the diagnostic cut-off of 6.5% [96-99]. The overlap 
between HbA1c and OGTT results was reported to be quite low [100, 101]. The ADA hope 
that greater practicality and convenience of the test would offset the low sensitivity of the test 




1.6 Prevalence of diabetes mellitus 
1.6.1 Global burden of diabetes mellitus and its risk factors 
T1DM comprises around 5–10% of DM cases [3]. T2DM accounts for approximately 90% of 
DM cases in all ages throughout the world [2]. In 2012, T2DM caused directly 1.5 million 
and indirectly 2.2 million deaths worldwide, being the eighth leading cause of death in both 
sexes [102]. The prevalence of T2DM is increasing worldwide and the number of affected 
people has risen from 108 million people in 1980 [103] to 422 million people in 2014 
corresponding to 8.5% among adults >18 years [104]. The number of affected people 
worldwide is projected to increase to 592 million by the year 2035 [105]. Increasing global 
prevalence of T2DM is due to various factors like population growth, aging of societies, 
increasing risk factors for T2DM (e.g. obesity, sedentary lifestyle), more effective diagnostic 
instruments and case-finding schemes and increased longevity of the diseased [106]. Excess 
body fat, reflecting several aspects of diet and physical activity, is mentioned as the strongest 
risk factor for T2DM worldwide [106]. In 2014, it was estimated that globally one in three 
adults over 18 years were overweight and more than one in ten were obese [107]. At the same 
time, physical inactivity became a great concern throughout the world. Based on data from 
2010, it was estimated that 27% of women and 20% of men from all countries were 
insufficiently physically active [107]. In 2017, health authorities in Norway reported that only 
around one third of Norwegian adult population applied the recommendations regarding 
physical activity [108]. 
1.6.2 Prevalence of type 2 diabetes mellitus in Europe 
While in 1980 the estimated prevalence of T2DM among adults >18 years in Europe was 
5.3%, this figure reached 7.3% in 2014 [106]. Data suggest that the incidence and prevalence 
of T2DM in European countries is frequently higher among people of lower socioeconomic 
status and these inequalities were mediated by BMI [109]. It should be mentioned that the 
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proportion of undiagnosed cases of T2DM varies widely from country to country and even in 
high-income countries this proportion might be as high as 30–50% [110]. A systematic 
review and meta-analysis study revealed that the prevalence of T2DM among ethnic minority 
groups resident in Europe was considerably higher than in ethnic Europeans [111].  
1.6.3 Prevalence of diabetes mellitus in Norway 
In 2004, the prevalence of known cases of any type DM in Norwegian adults over 30 years 
old was estimated 3.4% [11]. This estimate was based on data from nine regional surveys. 
The authors estimated also that the number of unknown cases might be nearly equal to the 
number of known cases in the age group ≥30 years old. According to the Norwegian Institute 
of Public Health, in 2017, approximately 245,000 (4.7%) Norwegians had known DM, of 
which 216,000 were estimated to have T2DM [112]. The annual number of new users of 
glucose-lowering agents in Norway is reported around 15,000–16,000 [113]. A recent 
nationwide cohort study based on national registries in Norway showed that the prevalence of 
known T2DM among inhabitants aged 30–89 years increased from 4.9% in 2009 to 6.1% in 
2014 [10]. According to this study, at the same time, the incidence of known cases of the 
disease decreased significantly from 609 cases per 100,000 person-years in 2009 to 398 cases 
per 100,000 in 2014, an annual reduction of 10.1%. This decline was observed for both 
pharmacologically and non-pharmacologically treated T2DM and in all sex, age, education 
level and place of birth subgroups [10]. In 2006, the third Nord-Trøndelag Health Survey  
(HUNT 3) reported the prevalence of any type DM in adults aged 20 years and over living in 
the county of Nord-Trøndelag to be 4.3% [114]. In 2011, the direct costs of DM treatment in 
Norway reached €408 million; and indirect costs reached €108 million [115].  
It is worth mentioning that, like in many other countries and societies, the prevalence of DM 
is not homogenous across Norway or even within its cities and districts. Results from three 
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population-based, cross-sectional studies conducted between 2000 and 2002 in Oslo revealed 
that the prevalence of self-reported adult DM was strikingly different between inhabitants of 
West and East Oslo [116]. While Western parts of Oslo have traditionally been inhabited by a 
wealthy, highly educated and ethnically homogeneous community, the historically 
disadvantaged and much more densely populated ‘East’ is popularly associated with 
immigration and social stigma [116]. According to the mentioned study, while the prevalence 
of self-reported DM in the Western parts of Oslo was 1.6%, this prevalence was 5.4% in the 
Eastern parts. The observed spatial disparity in the prevalence of DM remained highly 
significant even after adjustment for a range of covariates such as ethnicity, age or BMI. The 
results showed that ethnicity is a strong predictor for DM with being of non-Western origins 
increases the odds by a factor of almost 5 [116].  
1.6.4 Diabetes among indigenous peoples 
Higher prevalence and incidence of T2DM among indigenous peoples compared with 
benchmark populations worldwide seems to be a common phenomenon [117]. Indigenous 
peoples throughout the world are experiencing an unprecedented epidemic of T2DM [117]. 
While incidence rates of T2DM have been on the rise during the last decades, the disease 
disproportionately affects different racial and cultural groups [118]. 
The prevalence of self-reported DM among indigenous Australians aged ≥ 40 years was 
37.3% (95% confidence interval (CI): 34.6–40.2%) in 2008, which was more than eight times 
higher than that in non-indigenous Australians [25]. This happens in spite of the fact that the 
prevalence of DM was extremely uncommon among Australian indigenous populations some 
30 years ago (the rate was 10% of national rate) [117, 119]. A systematic review reported a 
great variation in the prevalence of DM between different segments of the Australian 
Indigenous population [120]. According to this study, the prevalence of (any type) DM was 
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greater among Indigenous Australian women compared to men and in remote compared to 
urban settings. A great deal of the disparities in the prevalence of DM can be attributed to 
disadvantageous socioeconomic status of indigenous people in Australia [121].  
While the overall age-standardised prevalence of DM in Canada in 2008–2009 was 6.8%, the 
age-standardised prevalence of DM was 17.2% among First Nations people living on-reserve, 
10.3% among those living off-reserve and 7.3% among Métis [122]. The corresponding 
prevalence among Inuit was similar to that of the general Canadian population [122]. 
Although the prevalence of DM in Canadian Inuit is now comparable to the general Canadian 
population, it was around 2% in 2001 [122]. The age-standardised prevalence of diagnosed 
DM increased 35% among adults aged > 20 years residing in rural Status Aboriginals in 
Alberta, Canada, from 10.9% (95 % CI: 10.4–11.5) in 1995 to 14.7% (95% CI: 14.2–15.2) in 
2006. Corresponding prevalence in urban Status Aboriginals increased by 22% from 9.4% 
(95% CI: 8.5–10.3) in 1995 to 11.5% (95% CI: 10.9–12.1) in 2006 [123].  
The Greenland population is a population isolate. While the prevalence of T2DM in 
Greenland was at a very low level in the 1960s, a study by Jørgensen et al. revealed that 
around 9% of adult (≥ 18 years) Inuit in Greenland suffered from DM in 2005–2010 with 
79% of them being previously undiagnosed [124]. This prevalence is almost twice as high as 
the prevalence of T2DM in Denmark, a country that Greenland is culturally and politically 
linked to [125]. The study showed also an inverse correlation between the prevalence of DM 
and urbanisation with people of lower socioeconomic status living in small towns and villages 
being at higher risk. The high prevalence of T2DM in Greenland is despite the fact that 
Greenlanders mostly consume a traditional Inuit diet with a high content of marine mammals 
and fish [126]. Therefore, changes in traditional lifestyle risk factors cannot fully explain the 
high prevalence of T2DM in Greenland and some genetic risk factors might be involved as 
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well [127]. A newly performed association mapping of T2DM-related quantitative traits 
among 2575 Greenlandic DM-free individuals discovered a nonsense p.Arg684Ter variant in 
the gene TBC1D4 with an allele frequency of 17% [128]. According to authors of the study, 
homozygous carriers of this variant have significantly higher concentrations of plasma 
glucose and serum insulin 2 hours after an oral glucose load compared with individuals with 
other genotypes. Increasing number of p.Arg684Ter alleles leads to a severely decreased 
insulin-stimulated glucose uptake in skeletal muscles, leading to postprandial 
hyperglycaemia, impaired glucose tolerance and T2DM [128]. In recent years, the quality of 
DM health care in Greenland has improved and the prevalence of diagnosed DM has 
increased since 2008 due to heightened awareness, increased funding and case-finding 
schemes [129].   
While T2DM was probably uncommon among American Indian and Alaska Native (AI/AN) 
populations before the 1940s [130] it was reported that in 2010 AI/AN had a higher rate (over 
14%) of diagnosed T2DM than any other racial or ethnic group in the USA [131]. At the 
same time, the prevalence of overweight and obesity was also reported to be higher among 
AI/AN compared to White or Hispanic Americans [22, 132]. Diabetes-related mortality rates 
are three times higher among AI/AN compared with White Americans [133] and DM is the 
fifth leading cause of death among AI/AN [22]. A study performed by Fretts et al. revealed 
that around half of American Indians developed DM by age 55 years and a high proportion of 
those affected by DM remained undiagnosed [134]. Fretts et al. reported also in the same 
study that of 2001 adult (aged 19–74) AI/AN free of DM and cardiovascular diseases 
recruited in the study and followed for 8 years, 243 individuals (12.1%) developed DM with 
consuming processed meat being a significant risk factor for developing DM among AI/AN 
(OR: 1.63).  
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The incidence rates of T2DM among Pima Indians in Arizona aged 5 years or older was as 
high as 25 cases/1000 person-years between 1965 and 2003 [135]. They feature a classic and 
well-known example of high incidence and prevalence of a subtype of T2DM characterized 
by obesity, insulin resistance, and a relative insulin deficiency [136]. Just like many other 
indigenous peoples, they have experienced a transition from a traditional lifestyle with low-
calorie diet and high physical activity to a sedentary lifestyle with high calorie intake [137]. 
Like Inuit in Greenland, Pima Indians are a population isolate, i.e. the population is derived 
from a small number of individuals with limited connection to other populations [137]. 
Generally, such populations exhibit a unique profile of rare diseases [138], and the prevalence 
of common diseases like T2DM might also be strikingly different from large, open 
populations [127]. Isolated populations are more vulnerable to rapid changes in the 
environment and lifestyle [127]. 
Unlike Inuit in Greenland and Pima Indians in the USA, Sami people in Norway have not 
been an isolated population, neither geographically nor genetically. Throughout the history, 
they have been in constant interaction with surrounding populations and now they live well-
integrated lives as part of Norwegian society [139]. The prevalence of metabolic syndrome 
among both Sami and non-Sami inhabitants of Northern Norway was reported to be high in 
the SAMINOR 1 Survey [13]. While, according to this survey, the prevalence of self-reported 
DM was not different between the Sami and non-Sami groups, ethnicity appeared to affect 
DM treatment, which was more prevalent among Sami than non-Sami women.   
In the Finnmark Study (1993) and the SAMINOR 1 and 2 Surveys, Sami women reported 
lower leisure-time physical activity than their non-Sami counterparts, while both Sami men 




The concept of ethnicity is multifaceted. Self-defined ethnicity depends on the context the 
definition has been shaped and applied in and may change over time [143]. According to 
various sources, ethnicity can be defined as a group of individuals who identify themselves 
and have a sense of belonging to each other based on some similarities like assumed common 
ancestry, language, dialect, society, culture, religion, mythology, rituals, nation, history, 
homeland, dressing style, art, and physical appearance [144-147]. The complexity of 
individual identity makes writing with precision about ethnicity challenging [148]. The 
ethnicity is not a mutually exclusive concept and one may be assigned to or conceive 
his/herself as member of different ethnic groups according to country of origin, ancestry, 
birthplace, language and so on [149]. Bhopal in his book on race and ethnicity emphasises 
that in most cases the differences between individuals belonging to a certain ethnic group are 
larger than the differences between different ethnic groups [149]. This results in ethnic 
categories being broad with overlapping and obscure borders [148]. Due to these issues, it has 
been recommended that researchers should elaborate on how and on what basis they defined 
the ethnic groups [150].  
Each definition of a given ethnic group relies on one or a few main feature(s) of that group 
and may in addition make use of other less important distinguishing features to further define 
the group. This may lead to having different definitions of an ethnic group, which might 
adversely affect results and comparisons. To ensure that any observed difference between 
ethnic groups is a result of real differences in the concerned endpoint of the study and not the 
applied definition of the ethnic group, sensitivity analyses can be helpful to avoid spurious 




1.8 The Sami people in Norway 
The Sami are an indigenous people who have traditionally inhabited northern parts of 
Norway, Sweden and Finland, and in Russia’s Kola Peninsula [152]. In Norway, their 
settlement area, Sápmi, encompasses Finnmark county in the north to Engerdal in Hedmark 
county in the south. According to Norwegian legislation, the Sami people are recognised as 
indigenous people [153]. Although there is no ethnic registry in Norway, it is estimated that 
the largest population of Sami people (proposed to be around 40,000) live in Norway [154]. 
The Sami people have traditionally pursued various livelihoods including reindeer husbandry, 
small-scale fishing, and agriculture [155, 156]. Today Sami people are active in almost all 
professions and only less than 10% of them are actively pursuing the traditional practices 
[157]. The Sami people in Norway consists of heterogeneous groups such as North, 
East/Skolt, Lule, Ume and South Sami, with various cultural, linguistic, and dietary features 
[158].  
The history of Sami people has many similarities with the histories of other indigenous 
peoples throughout the world. The Sami people have for centuries been subject to 
discrimination and for more than 100 years victims of an official assimilation policy exerted 
by the Norwegian government. Motivation for this policy was “Social Darwinism” and 
national romantic ideologies [159]. Some areas like the areas bordering Russia and Finland as 
well as coastal Sami areas of Northern Troms and Finnmark were more exposed to this so-
called Norwegianisation policy [155, 159, 160]. The education system was one of the most 
effective tools for Norwegian authorities to enforce this policy by banning the Sami language 
at schools and removing Sami children from their cultural and linguistic environments [161, 
162]. Besides linguistic policies, Norwegian authorities encouraged thousands of people from 
other parts of Norway to immigrate and settle in Finnmark county, which turned Sami people 
into minority groups in their own traditional territories at the coastal areas [163]. During the 
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19th and 20th centuries, fishing industry, which traditionally was one of main livelihoods of 
Sami people in coastal areas, became industrialised. This had profound economic as well as 
lifestyle impact on Sami inhabitants in coastal areas [164]. The evacuation of coastal areas 
during and ensuing the second World War in tandem with rapid modernisation process 
occurring in almost all aspects of labour market did put extra pressure on Sami language and 
culture [155].  
Nowadays, many Sami people are active in administrative and service sectors and almost the 
entire reindeer husbandry and agriculture are mechanised with less physical activity involved 
[165]. The pro-Sami movements and revitalisation policies implemented from 1960s have, to 
some extent, managed to reverse the adverse effects of the past Norwegianisation policies 
[139]. The changes in lifestyle towards so-called western and sedentary lifestyle with 
unhealthy diet, which have affected all ethnic groups in the region, have continued in the 
same direction until now [166]. Like a two-edged sword some of these changes have been 
unfavourable, others have had beneficial effects on the health situation.  
The abovementioned colonisation, assimilation and marginalisation policies exerted on Sami 
people throughout the history might have made them more vulnerable to adverse health 





1.9 The Sami people and health studies 
Research on the Sami people was started in the early 1800s by gathering skeletal material 
from archaeological excavations and autopsies at the Department of Anatomy, the University 
of Oslo, Norway [168]. These so-called research activities focused on racial attributes and 
used cranial indices and skull measurements with the intention of distinguishing ethnic 
groups. Rather than investigating Sami's lifestyle and culture, they tried to use physio-
anthropological features to provide a scientific evidence for the superiority of the benchmark 
population. This discriminatory and racist approach to scientific methods left a deep 
impression on many Sami people causing them to distrust researchers [168]. 
Since the Second World War, a growing political awareness and generally higher levels of 
education among the Sami people, in combination with increasing interest and involvement of 
researchers with Sami affiliations have paved the way for new studies on Sami health issues 
with a totally different approach and ethical principles [168]. The first population-based study 
conducted in the Sami regions was the different surveys of the Finnmark Study (1974–2000), 
which included all ethnic groups living in the Finnmark county [169]. Before the Finnmark 
Study, only some isolated reports from practitioners working in North-Sami regions were 
published, reporting issues such as tuberculosis, echinococcosis and high rates of infant 
mortality [170-172]. 
The establishment of the Centre for Sami Health Research at UiT the Arctic University of 
Norway in 2001 was the turning point in meeting the increasing need for knowledge about 
Sami peoples’ health and living conditions. Ever since, the centre has collaborated with 
several regional, national and international actors in the field of research among Sami or other 
indigenous peoples and facilitated a substantial increase in publications and reports in this 




Kvens are descendants of Finnish ethnicity who immigrated from Sweden and Finland to 
Norway and settled in the northern parts of Norway in the 1700s and 1800s [175]. Since 
1998, Kvens are recognised as a national minority in Norway [176]. The Kvens in Norway do 
not have indigenous status like the Sami. Similar to the Sami people, the Kvens have also 
experienced linguistic and cultural assimilation in the Norwegian society and enormous 
changes in lifestyle and way of living during the past centuries and decades. A large number 
of Kvens mentioned in the questionnaire affiliations to either Sami or Norwegian ethnic 
groups besides their main ethnicity. Due to relatively small number of Kvens in our surveys, 




1.11 The aims of the thesis 
The inspiration and motivation for the present thesis was the paucity of publications regarding 
the incidence and prevalence of DM among the Sami people inhabiting rural districts in 
Norway, and several publications reporting higher incidence and/or prevalence of lifestyle 
related diseases, especially T2DM, among other indigenous peoples throughout the world. 
The overall aim of the thesis is to assess the burden of DM among Sami and non-Sami 
inhabitants of Northern Norway.    
The specific aims of the thesis are:  
1) To measure the prevalence of pre-diabetes and DM among inhabitants of the included 
municipalities of Northern Norway in two points of time; the SAMINOR 1 Survey 
(2003–2004) and the SAMINOR 2 Clinical Survey (2012–2014); 
2)  To explore any ethnic difference between Sami and non-Sami inhabitants of these 
municipalities in terms of dysglycaemia;   
3) To determine the 8-year cumulative incidence of DM from the SAMINOR 1 Survey 
(2003–2004) to the SAMINOR 2 Clinical Survey (2012–2014); 
4) To elucidate some possible explanatory factor(s) behind any ethnic difference in the 






2.1 The SAMINOR 1 Survey 
In 2003–2004, the Centre for Sami Health Research at UiT The Arctic University of Norway, 
in collaboration with the Norwegian Institute of Public Health, conducted the SAMINOR 1 
Survey, a cross-sectional population-based survey on health and living conditions in regions 
with both Sami and Norwegian populations [177]. The survey was first designed and planned 
as a cardiovascular screening in Northern Norway by the National Health Screening Service 
and then by joining the Centre for Sami Health Research took the form of the SAMINOR 1 
Survey. This survey included municipalities and districts in Norway with a high proportion of 
people with Sami ethnicity, as determined by ethnicity and language information reported in 
the 1970 census and historical and local knowledge about traditional Sami settlements [178]. 
The included municipalities were: Karasjok, Kautokeino, Tana, Nesseby, Porsanger, Lebesby, 
Loppa, Kvalsund, Alta, Lyngen, Storfjord, Kåfjord, Kvænangen, Lavangen, Skånland, 
Narvik, Evenes,Tysfjord, Hattfjelldal, Røyrvik, Namsskogan, Grane, Snåsa and Røros (Figure 
3). These municipalities are all except the Alta municipality located in rural areas. Only some 
districts of Hattfjelldal, Grane, Narvik, Namsskogan, Snåsa and Røros municipalities with 
considerable proportion of Sami inhabitants were included in the survey.  
An invitation was mailed several weeks before the survey with information on the time and 
place of screening, relevant and required information about the survey, and questionnaires. 
The questionnaires were returned by the participants at the time of the clinical examination 
[177]. All residents aged 30 and 36–79 years registered in the National Registry in the 
selected regions were invited to participate in the SAMINOR1 Survey regardless of their 
ethnic background (n=27,987). Due to the small sample size and low participation rate among 
30-year-old inhabitants – only 328 participants out of the 836 invited (39.2%) – , they were 
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excluded from analyses (DM prevalence estimates) in the first paper. Of the remaining 
individuals, 16,538 participated and gave consent to use their information in medical research 
(60.9%).  
The survey included a short clinical examination, blood sampling and three self-administered 
questionnaires: an initial two-page questionnaire that contained a variety of questions, 
including questions about ethnicity; a three-page screening questionnaire that collected 
information about symptoms, lifestyle factors, and some diseases, including DM; and an 
additional four-page questionnaire that collected cultural, social, and nutritional information. 
The English version of the SAMINOR 1 Survey questionnaire is available at 
www.saminor.no.   
In the first four municipalities, it was possible to participate with the initial questionnaire 
only, without taking part in the clinical examinations or fill in the main questionnaire. In 
addition, due to a design problem, some participants underwent clinical examinations without 
filling in the initial questionnaire. The questionnaires were prepared in Norwegian and 
translated into the three main Sami languages; however only the Northern Sami version was 
used in the six municipalities defined in the Sami Language Act at that time as the Sami 
Language Administrative District (Karasjok, Kautokeino, Tana, Nesseby, Porsanger, and 
Kåfjord). More than 98% of the participants completed the Norwegian version of the 
questionnaire. In 15 of the 24 municipalities, non-responders were offered a second chance to 
attend when the buses returned a couple of months later. Unlike inhabitants in Finnmark and 
Troms counties, inhabitants in Nordland and both Trøndelag counties did not receive a second 
invitation; thus, this design affected the participation rate in these areas.  
A trained team of experienced fieldworkers undertook the practical work. The clinical 
examination was carried out in two buses that moved throughout the study area, spending 1–6 
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weeks in each of the municipalities included in this analysis [177]. Non-fasting venous blood 
samples were drawn with the participants in a seated position. Participants came to the 
examination buses throughout the day, from 8 o’clock in the morning to 19 o’clock in the 
afternoon. The time after the last meal ranged from immediate after meal to 9 hours with 
average postprandial time a little over 2 hours. The samples were left to coagulate for a 
minimum of 30 minutes and were centrifuged within 1.5 hours. Serum was sent by overnight 
mail to the Department of Clinical Chemistry, Ullevål University Hospital, Oslo, Norway, 
where glucose was measured directly by an enzymatic method (Hitachi 917 autoanalyzer, 
Roche Diagnostic, Switzerland). Autonorm Human Liquid was used as internal quality 
control material. The control material was analysed at the start and for every 30th sample. 
During physical examination, height (to the nearest 0.1 cm) and weight (to the nearest 100 
grams) were measured with an electronic height and weight scale (DS-102, Dong Sahn Jenix, 
Seoul, Korea) with the participant wearing light clothing without shoes. Body mass index 
(BMI, kg/m2) was calculated as weight (kg)/(height (m))2 to the nearest 0.1 unit. Waist 
circumference (WC, cm) was measured at the umbilicus level to the nearest centimetre at the 




Figure 3. The map of the included municipalities and the 4 defined geographical regions. The SAMINOR 1 
Survey. Published with permission from Centre for Sami Health Research. 
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2.2 The SAMINOR 2 Survey 
The Centre for Sami Health Research conducted also the SAMINOR 2 Survey, which 
consisted of two parts. The first part of this survey, the SAMINOR 2 Questionnaire Survey, 
was purely questionnaire-based and was conducted in year 2012 among inhabitants aged 18–
69 years from the same 24 municipalities and districts included in the SAMINOR 1 Survey in 
addition to the municipality of Sør-Varanger [179]. The second part of the survey, the 
SAMINOR 2 Clinical Survey was conducted in 2012–2014 and consisted of self-administered 
questionnaires, a clinical examination, and analysis of blood samples. The survey included 
individuals aged 40–79 years old from 10 municipalities of Finnmark, Troms, and Nordland 
counties: Kautokeino, Karasjok, Porsanger, Tana, Nesseby, Storfjord, Kåfjord, Lyngen, 
Skånland, and Evenes (Figure 4). Please note that these 10 municipalities were included also 
in the SAMINOR 1 Survey and the SAMINOR 2 Questionnaire Survey.  
Like in the SAMINOR 1 Survey, an invitation was mailed several weeks in advance to 
eligible inhabitants of the designated municipalities along with pertaining information about 
the provided questionnaires and the time and place of the clinical examination. Participants 
were asked to present their completed questionnaires at the time of the clinical examination, 
which was performed at one of 10 research stations established in 9 municipalities (two 
research stations were set up in Kåfjord municipality in the communities of Manndalen and 
Birtavarre; participants living in Evenes visited the research station in neighbouring 
Skånland). In total, 12,455 were invited, and 6004 took part in the clinical examination. All 
the clinical examinations were performed within 2–7 weeks in each municipality.  
During the clinical examination, trained personnel measured participants’ height (to the 
nearest 0.1 cm) and weight (to the nearest 100 grams) using an electronic height and weight 
scale (DS-103, Dongsahn Jenix, Seoul, Korea) with participants wearing light clothing and no 
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shoes. These measures were then used to calculate body mass index (BMI, kg/m2). Waist 
circumference (WC, cm) was measured at the umbilicus to the nearest cm with the participant 
standing and breathing normally. Waist-to-height ratio (WHtR) was calculated by dividing 
the waist by the height. Finally, blood samples were collected by venepuncture at normal 
venous pressure, with participants in a seated position. Blood samples were stored at -20°C in 
a freezer and after some weeks transported to the biobank at UiT The Arctic University of 
Norway where the serum samples were stored at -70°C in ultra-freezers. Random plasma 
glucose was analysed at the Laboratory of the Department of Clinical Chemistry, University 
Hospital of North Norway, Tromsø, Norway in the period of September 2014 – November 
2014.  
Glucose was measured on the Cobas 8000 system from Roche/Hitachi using an in-vitro test 
for the quantitative determination of glucose in human serum. The test principle is an 
ultraviolet test with enzymatic references method with hexokinase. Glucose values for human 
serum obtained on the Roche/Hitachi c 701 analyser were compared with those determined 
using the same reagent on the Roche/Hitachi cobas 501 analyzer. This method has been 
standardised against isotope dilution mass spectrometry reference measurement procedure. 
The analyser automatically calculates the analyte concentration of each sample by conversion 
factor mg/dl x 0.0555= mmol/L. All reagents were purchased from the same company. 
Glycated haemoglobin (HbA1c) was analysed immediately on whole blood at the 
examination site, with The DCA Vantage™ (Siemens Medical Solutions Diagnostics, 
Tarrytown, NY), which is based on latex agglutination inhibition immunoassay methodology 
and provides results in 6 minutes. 
Questionnaires differed by age group: participants aged 40–69 years received an 8-page 
questionnaire that covered a broad range of questions on lifestyle, diet, risk factors, and 
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diseases. In contrast, participants aged 70–79 years received a 4-page questionnaire with 
larger fonts. Only questions that were identical in the two questionnaires were included in the 
present analyses. Both questionnaires were originally prepared in Norwegian and then 
translated into the Northern Sami language owing to the fact that all 10 municipalities belong 
to the Northern Sami language area. In Kautokeino, Karasjok, Nesseby, and Tana 
municipalities, participants received both the Sami and Norwegian versions of the 
questionnaire. In Kåfjord, Storfjord, Porsanger, and Lyngen municipalities, the questionnaire 
in the Northern Sami language was available on request. Invitees in Skånland and Evenes 
municipalities received the Norwegian questionnaire only. Among all of our participants, less 
than 5% chose to use the Sami version of the questionnaire. The English version of the 
SAMINOR 2 Clinical Survey questionnaire for 40–69-year-old participants is available at 
www.saminor.no. 
2.3 Ethics 
The Norwegian Data Protection Authority approved the SAMINOR 1 Survey and the 
SAMINOR 2 surveys. The surveys were approved by Regional Committees for Medical and 
Health Research Ethics (REC North). All participants gave a written informed consent, which 
also included a consent to later linkages to national registers, previous censuses and 
cardiovascular screenings. Information letters and brochures were elaborated in co-operation 
with the Norwegian Data Protection Authority and REC North. This specific diabetes study 




Figure 4. The map of the 10 municipalities included in the SAMINOR 2 Clinical Survey. Published with 





2.4 Definition of ethnicity 
In both surveys, information on ethnicity was obtained from the questionnaires with identical 
questions regarding ethnicity (Figure 5). The questions were: “What language(s) do/did you, 
your parents and your grandparents use at home?”, “What is your, your father’s and your 
mother’s ethnic background?”, and “What do you consider yourself to be?” On all items the 
response options were: “Norwegian”, “Sami”, “Kven”, and “Other”. The questions were to be 
answered separately for each relative and multiple answers were allowed. Sami ethnicity was 
defined based on two criteria: 1) self-identification as a Sami, and 2) a Sami language 
connection. Sami self-identification was regarded as fulfilled if the respondent considered 
him/herself to be Sami or reported having a Sami ethnic background. Sami language 
connection was defined if at least one grandparent, parent, or the participant him/herself 
spoke a Sami language at home. Participants who fulfilled both criteria were categorised as 
Sami. All other participants were categorised as non-Sami.  
To assess the reproducibility of answers to ethnicity questions, results from the SAMINOR 1 
and 2 Surveys were compared. Of a total of 3303 persons who participated in both the 
SAMINOR 1 Survey and the SAMINOR 2 Clinical Survey, respectively, and included in 
Paper 3, 1314 (39.8%) and 1317 (39.9%) reported having Sami ethnicity with a high 











2.5 Paper 1 
2.5.1 Study participants 
Of the 27,151 inhabitants (36–79 years) who were invited to the SAMINOR 1 Survey, 16,538 
(60.9%) agreed to participate. After exclusion of those with either missing ethnicity variable 
or outcome variable (self-reported DM and/or non-fasting plasma glucose), 15,208 (56.0%) 
individuals were included in the study (Figure 6 and Table 1).  
 





Table 1. Characteristics of the invited (36–79 years old), participants, sub-groups and the final working sample in 
paper 1. The SAMINOR 1 Survey 












Paper 1 (%) 
Number 27,151 16,538 15,718 15,515 15,208 
Percent  60.9 57.9 57.1 56.0 
 
Sex      
 Men 14114 (52) 7985 (48) 7529 (48) 7444 (48) 7315 (48) 
 Women 13037 (48) 8553 (52) 8189 (52) 8071 (52) 7893 (52) 
 
Age (years)      
 36–49 10748 (40) 6040 (37) 5722 (36) 5654 (36) 5492 (36) 
 50–59 7739 (28) 5063 (31) 4833 (31) 4773 (31) 4681 (31) 
 60–79 8664 (32) 5435 (33) 5163 (33) 5088 (33) 5035 (33) 
 
Regions*      
 1 2704 (10) 1777 (11) 1366 (9) 1190 (8) 1169 (8) 
 2 4174 (15) 2687 (16) 2301 (15) 2283 (15) 2221 (15) 
 3 14078 (52) 8647 (52) 8631 (55) 8624 (56) 8465 (56) 
 4 6195 (23) 3427 (21) 3420 (22) 3418 (22) 3353 (22) 
 
Marital status      
 Single 6472 (24) 3202 (19) 2952 (19) 2903 (19) 2842 (19) 
 Married 15175 (56) 10259 (62) 9848 (63) 9728 (63) 9535 (63) 
 Widow(er) 1826 (7) 1066 (6) 1015 (6) 992 (6) 979 (6) 
 Divorced 3054 (11) 1704 (10) 1614 (10) 1606 (10) 1574 (10) 
 Separated 623 (2) 307 (2) 289 (2) 286 (2) 278 (2) 
 Missing 1 0 0 0 0 
 
Ethnicity      
 Sami  3932 (24) 3406 (22) 3406 (22) 3398 (22) 
 Non-Sami  12095 (74) 11831 (77) 11831 (77) 11810 (78) 
 Other  240 (1) 226 (1) 226 (1) 0 
 Missing  271 255 52 0 
 
Education      
 0–7 years  2551 (17) 2543 (17) 2474 (17) 2454 (17) 
 8–12 years  7469 (51) 7452 (51) 7373 (51) 7265 (51) 
 13+ years  4757 (32) 4749 (32) 4708 (32) 4562 (32) 
 Missing  1761 974 960 927 
*Region 1: Karasjok and Kautokeino municipalities;  
Region 2: Porsanger, Tana and Nesseby municipalities;  
Region 3: Lyngen, Storfjord, Kåfjord, Kvænangen, Alta, Loppa, Kvalsund and Lebesby municipalities;  
Region 4: Lavangen, Narvik, Evenes, Skånland, Tysfjord, Hattfjelldal, Røyrvik, Namsskogan, Grane, Snåsa and 




Both questionnaire information and non-fasting plasma glucose measurements were used to 
categorise participants as normoglycaemic, with pre-diabetes or DM. The question about DM 
was: “Do you have, or have you ever had diabetes?” Those who reported in the questionnaire 
that they currently have or previously had DM were classified as having DM. Missing 
answers were regarded as “no”. In addition, a random (non-fasting) plasma glucose 
measurement was used for ascertaining dysglycaemia. Participants with non-fasting plasma 
glucose levels of 11.1 mmol/L or higher were also classified as having DM, and those with a 
level of 7.8–11.0 mmol/L were classified as having pre-diabetes. The remaining participants 
were categorised as normoglycaemics.  
 
2.5.3 Geographical regions 
Four geographical regions were defined: “Region 1” consisted of areas in the inland of 
Finnmark county, including Karasjok and Kautokeino municipalities. “Region 2” consisted of 
both inland and coastal areas in Finnmark county, including Porsanger, Tana, and Nesseby 
municipalities. “Region 3” consisted of coastal areas in Finnmark and the northern part of 
Troms county, including Lyngen, Storfjord, Kåfjord, Kvænangen, Alta, Loppa, Kvalsund, and 
Lebesby municipalities. “Region 4” consisted of Marka, Lule, and South Sami areas in 
southern Troms, Nordland, Nord- and Sør-Trøndelag counties, including Lavangen, Narvik, 
Evenes, Skånland, Tysfjord, Hattfjelldal, Røyrvik, Namsskogan, Grane, Snåsa, and Røros 




2.5.4 Statistical analysis 
Using the direct method, the European standard population of 2013 was used to age-
standardise the prevalence values. Hence, these results may be compared with multiple 
studies as the European standard population is frequently used as reference. As the outcome 
variable (dysglycaemia) had three categories (diabetes, pre-diabetes, normoglycaemia), 
multinomial logistic regression analysis stratified by sex (and separately for four geographic 
regions) and adjusted for age was applied to determine the age-adjusted odds ratio (OR) for 
pre-diabetes and DM for Sami compared with non-Sami.  
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2.6 Paper 2 
2.6.1 Study participants 
Regardless of ethnic background, all inhabitants aged 40–79 years from the 10 municipalities 
included in the SAMINOR 2 Clinical Survey were invited to participate. Of the 12,455 
invited, 6004 (48.2%) attended the clinical examination. After exclusion of those with 
uncompleted questionnaire (n=21), missing HbA1c results (n=22), missing ethnicity variable 
(n=72), and those with T1DM (n=11), 5878 individuals (47.2%) were included in the analyses 
(Figure 7, Table 2).  
2.6.2 Type 2 diabetes mellitus 
Information about DM was obtained from both questionnaires and HbA1c results. In the 
questionnaires, this information came from the question: “Have you ever been diagnosed with 
diabetes (elevated blood sugar levels)?” The available answers were “yes” or “no”. Missing 
values were classified as “no”. If the participant answered “yes”, they were asked about the 
type (T1DM, T2DM, or gestational diabetes). In addition to participants who reported T2DM, 
those who reported DM without specifying the type (56 participants) were also categorised as 
having T2DM. Moreover, those who reported having T1DM and reported taking glucose-
lowering medication for its treatment (26 participants) or never using insulin (6 participants), 
were recategorised as having T2DM.  
In addition, those with HbA1c ≥ 6.5% were categorised as having T2DM. As virtually all 
individuals with T1DM are aware of their disease and are under treatment, all those who had 
high HbA1c (≥ 6.5%) without reporting DM in the questionnaires were regarded as having 




2.6.3 Geographical regions 
The 10 municipalities were divided into three different regions: Region 1 consisted of areas in 
the inland of Finnmark county, including Karasjok and Kautokeino. Region 2 was comprised 
of both inland and coastal areas in Finnmark county, including Porsanger, Tana, and Nesseby. 
Region 3 consisted of the remaining municipalities (Evenes, Skånland, Lyngen, Storfjord, and 
Kåfjord) (Figure 4). 
2.6.4 Statistical analysis 
Differences in mean age, education, physical activity score, height, weight, WHtR, BMI, and 
WC by sex and ethnic groups were assessed using two-sample t-tests. Self-reported DM and 
categorised HbA1c were compared between groups using χ2 tests. The direct method was 
used to age-standardise the prevalence of pre-diabetes and T2DM. To obtain estimates that 
better reflect the true prevalence values of T2DM in the selected municipalities and age 
groups, invitees in the SAMINOR 2 Clinical Survey were chosen as the standard population 
(age groups: 40–59, 60–69 and 70–79 years). Prevalence of pre-diabetes and T2DM by sex, 
age, and ethnic groups were presented as percentages with 95% confidence interval (based on 
normal approximation). Multinomial logistic regression analysis was used to calculate the 
odds ratio (OR) with 95 % CI of pre-diabetes and T2DM for Sami compared to non-Sami 











Table 2. Characteristics of the invited (40–79 years), participants, sub-groups, and working samples of paper 2, 







and questionnaire (%) 
Included in 
Paper 2 (%) 
Number 12,455 6004 5983 5878 
Percent  48.2 48.0 47.2 
 
Sex     
 Men 6469 (52) 2747 (46) 2732 (46) 2688 (46) 
 Women 5986 (48) 3257 (54) 3251 (54) 3190 (54) 
 
Age (years)     
 40–59  6810 (54) 2868 (48) 2851 (48) 2800 (48) 
 60–69 3589 (29) 2008 (33) 2004 (33) 1966 (33) 
 70–79  2056 (17) 1128 (19) 1128 (19) 1112 (19) 
 
Regions*     
 1 2616 (21) 1289 (21) 1288 (22) 1259 (21) 
 2 4034 (32) 2011 (33) 2011 (34) 1976 (34) 
 3 3605 (29) 1665 (28) 1651 (28) 1625 (28) 
 4 2200 (18) 1039 (17) 1033 (17) 1018 (17) 
 
Marital status     
 Married  3401 (57) 3401 (57) 3350 (57) 
 Cohabitant  859 (15) 859 (15) 843 (14) 
 Divorced  533 (9) 553 (9) 540 (9) 
 Unmarried  722 (12) 722 (12) 712 (12) 
 Widow(er)  389 (7) 389 (7) 380 (7) 
 Missing  80 59 53 
 
Ethnicity     
 Sami  2410 (41) 2410 (41) 2396 (41) 
 Non-Sami  3380 (57) 3380 (57) 3365 (57) 
 Other  118 (2) 118 (2) 117 (2) 
 Missing  96 75 72 
 
Education     
 0–7 years  672 (12) 672 (12) 669 (12) 
 8–12 years  2738 (48) 2738 (48) 2697 (48) 
 13+ years  2321 (40) 2321 (40) 2262 (41) 
 Missing  273 252 250 
*Region 1: Karasjok and Kautokeino municipalities;  
Region 2: Porsanger, Tana and Nesseby municipalities;  
Region 3: Lyngen, Storfjord, Kåfjord, Kvænangen, Alta, Loppa, Kvalsund and Lebesby municipalities;  
Region 4: Lavangen, Narvik, Evenes, Skånland, Tysfjord, Hattfjelldal, Røyrvik, Namsskogan, Grane, Snåsa and 
Røros municipalities  
 
48 
2.7 Paper 3 
2.7.1 Study participants 
Individuals aged 30 and 36–71 years in SAMINOR 1 from the same 10 municipalities who 
participated in both the SAMINOR 1 Survey (2003–2004) and the SAMINOR 2 Clinical 
Survey (2012–2014) were included in the analysis. The two data files were merged by 
Statistics Norway using the unique 11-digit personal identification numbers assigned to all 
individuals who live in Norway. The merged file contains individuals born 1933–1968 and 
1973 (i.e., aged 30 and 36–71 in the SAMINOR 1 Survey, and 40–41 and 44–79 in the 
SAMINOR 2 Clinical Survey). Due to collection of data over two calendar years in the 
SAMINOR 1 Survey and three calendar years in the SAMINOR 2 Clinical Survey, the time 
span between the two surveys varied from eight to eleven years, with a mean of 10.1 years.  
In the SAMINOR 2 Clinical Survey, 12,455 people, aged 40–79 years were invited to take 
part, and 6004 participated (48.2%). We lack information about those invited to the 
SAMINOR 2 Clinical Survey who had also participated in the SAMINOR 1 Survey, as a 
linkage was only allowed for those who participated in both surveys. Therefore, loss to 
follow-up is described based on the SAMINOR 1 Survey participants who would have been 
invited to the SAMINOR 2 Clinical Survey, given that they had not died or moved from the 
10 studied municipalities prior to invitation to the SAMINOR 2 Clinical Survey. There were 
11,558 invitees to the SAMINOR 1 Survey, who, according to their birth year and 
municipality, would have been invited to the SAMINOR 2 Clinical Survey, given that none 
had moved or died. Of these, 6450 (55.8%) participated in the SAMINOR 1 Survey clinical 
examinations, of whom 6408 gave their consent to register linkages. 
Among the 6408 individuals, 169 were excluded due to missing initial questionnaire, 2 with 
missing main questionnaire (containing diabetes information), and 27 with missing ethnicity 
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information in the SAMINOR 1 Survey. Based on self-report and random (non-fasting) 
plasma glucose (RPG) ≥ 11.1 mmol/L measurement in the SAMINOR 1 Survey, 260 
prevalent cases of DM were excluded. To ensure exclusion of prevalent cases, additionally 75 
participants were excluded, as they reported in the SAMINOR 2 Clinical Survey the time of 
DM diagnosis prior to (n=52), at the same time as (n=6) or during the first two years after 
participating in the SAMINOR 1 Survey (n=17, two years wash-out period). Of the remaining 
5875 persons, 11 were not included in the final analysis due to missing main questionnaire 
(n=10) or HbA1c measurement (n=1) in the SAMINOR 2 Clinical Survey. A total of 2561 
subjects from the SAMINOR 1 Survey did not participate in the SAMINOR 2 Clinical Survey 
as they died, moved out of the included municipalities during the follow-up period, or were 
not willing/able to participate. Hence, 3303 individuals were included in the analysis (Figure 







Table 3. Characteristics of the invited, participants, sub-groups and the final working sample in paper 3. The 
SAMINOR 1 and 2 Clinical Surveys 
 Invited 
(%) 
Participated in clinical 
examinations 




in both surveys (%) 
Included in 
analysis, 
Paper 3 (%) 
Number 11,558 6408 3624 3303 
Percent  55.4 31.4 28.6 
 
Sex     
 Men 6114 (53) 2998 (47) 1586 (44) 1447 (44) 
 Women 5444 (47) 3410 (53) 2038 (56) 1856 (56) 
 
Age (years)     
 30 336 (3) 111 (2) 51 (1) 45 (1) 
 36–49 4978 (43) 2525 (39) 1329 (37) 1243 (38) 
 50–59 3807 (33) 2285 (36) 1425 (39) 1302 (39) 
 60–71 2437 (21) 1487 (23) 819 (23) 713 (22) 
 
Marital status     
 Single 3378 (29) 1435 (22) 711 (20) 652 (20) 
 Married 6218 (54) 3931 (61) 2364 (65) 2158 (65) 
 Widow(er) 440 (4) 266 (4) 146 (4) 126 (4) 
 Divorced 1253 (11) 650 (10) 332 (9) 300 (9) 
 Separated 268 (2) 126 (2) 71 (2) 67 (2) 
 Missing 1 0 0 0 
 
Ethnicity     
 Sami  2464 (38) 1452 (40) 1314 (40) 
 Non-Sami  3887 (61) 2145 (59) 1989 (60) 
 Missing  57 (1) 27 (1) 0 (excluded) 
 
Education     
 0–7 years  825 (13) 459 (13) 400 (12) 
 8–12 years  3180 (50) 1810 (50) 1637 (50) 
 13+ years  2058 (32) 1222 (34) 1132 (34) 




Figure 8. Participants in the SAMINOR 1 Survey, exclusions, those we would want to follow up, and, finally, those 





2.7.2 Diabetes mellitus 
In the SAMINOR 1 Survey, both questionnaire information and random (non-fasting) plasma 
glucose (RPG) levels were used to categorise participants as having DM. In the SAMINOR 1 
Survey, the question concerning DM was: “Do you have or have you had diabetes?” In the 
SAMINOR 2 Clinical Survey, the question was: “Have you ever been diagnosed with 
diabetes (elevated blood sugar levels)?” The available answers were “yes” or “no”. Missing 
values were classified as “no”.  
All those who in the SAMINOR 1 Survey reported that they had DM as well as those with 
RPG levels ≥ 11.1 mmol/l were excluded from the analyses (They were prevalent cases). In 
addition, and as discussed above, those who in the SAMINOR 2 Clinical Survey reported the 
time of DM diagnosis as prior to, at the same time as or during the first two years after 
participating in the SAMINOR 1 Survey (wash-out period) were regarded as prevalent cases 
of DM in the SAMINOR Survey and were excluded from the final analysis. Thus, the follow-
up time was around eight years.   
In the SAMINOR 2 Clinical Survey, self-report and glycated haemoglobin (HbA1c ≥ 6.5%) 
were used to identify incident cases of DM. By dividing the number of incident cases of DM 
in the SAMINOR 2 Clinical Survey by the DM-free individuals in the SAMINOR 1 Survey, 
the 8-year cumulative incidence of DM was calculated.  
2.7.3 Risk factors of type 2 diabetes mellitus 
At the entrance of the SAMINOR 1 Survey, some potential risk factors for T2DM like age, 
BMI, WC, WHtR, family history of DM, marital status, education level, smoking, alcohol 
consumption, mental distress (Hopkins symptom checklist (SCL-10 score)), physical activity, 
and gross family income were measured or asked about. The levels of these risk factors were 
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compared in those who were finally included in the analysis with those who were not 
included. The same was done for Sami versus non-Sami participants in the final analysis.   
2.7.4 Statistical analysis 
Logistic regression analysis was used to assess the effect of ethnicity as well as available and 




3 Summary of the results 
3.1 Paper 1 
Of the 15,208 participants in the SAMINOR 1 Survey included in the study sample, 696 
(4.6%) were defined as having DM, and 426 (2.8 %) as having pre-diabetes. Among those 
defined as having DM, 636 (91.4%) reported DM in the questionnaire, whereas 60 (8.6%) 
were identified only by non-fasting plasma glucose. 
Little or no ethnic difference was observed in the total age-standardised prevalence of pre-
diabetes or DM in either sex. Total age-standardised prevalence of pre-diabetes and DM for 
Sami men was 3.4% and 5.5%, respectively. Corresponding values for non-Sami men were 
3.3% and 4.6%. Total age-standardised prevalence of pre-diabetes and DM for Sami women 
was 2.7% and 4.8%, respectively, while corresponding values for non-Sami women were 
2.3% and 4.5%.  
In Region 1, the age-adjusted odds of having DM was significantly lower among Sami men 
than among non-Sami men (OR=0.29, 95% CI=0.10–0.82). The same was observed for Sami 
women in Region 2 (OR=0.46, 95% CI=0.23–0.91). In Region 4, the situation was opposite, 
with the age-adjusted odds for DM being significantly higher in both Sami men and women 
than in their non-Sami counterparts [OR=2.87 (95% CI=1.63–5.06) for men and OR=2.38 
(95% CI=1.28–4.43) for women]. Odds for pre-diabetes was also significantly higher for 




3.2 Paper 2 
Based on self-report and/or HbA1c-measurements, a total of 2083 (35.4%) individuals were 
defined to have pre-diabetes and 565 (9.4%) to have T2DM in the SAMINOR 2 Clinical 
Survey. Of those who were categorised as having T2DM, 465 (82.3% of all cases) reported 
T2DM or elevated blood sugar levels in the questionnaire. The total age-standardised 
prevalence of pre-diabetes and T2DM were, respectively, 34.1% (95% CI: 33.1–35.1) and 
8.7% (95% CI: 8.0–9.4).  
In men, the total age-standardised prevalence of pre-diabetes (37.9% vs 31.4%) and T2DM 
(10.8% vs 9.5%) were higher in Sami compared with non-Sami. When adjusting for age as a 
continuous variable in a multinomial logistic regression analysis, the ethnic difference was 
statistically significant for both pre-diabetes (OR 1.42, 95 % CI: 1.20–1.68) and T2DM (OR 
1.31, 95% CI: 1.01–1.70).  
In women, pre-diabetes (36.4% vs 33.5%) and T2DM (8.6% vs 7.0%) were also more 
prevalent in Sami than non-Sami. The ethnic differences in both pre-diabetes (OR 1.20, 95% 
CI: 1.02–1.41) and T2DM (OR 1.38, 95% CI: 1.05–1.82) were also herein statistically 
significant.  
Adjustment for WHtR had the largest impact on the OR for pre-diabetes and T2DM for Sami 
compared to non-Sami, especially in women; after adjusting for WHtR, the OR for pre-
diabetes in women was 1.05 (p=0.59) and for T2DM 1.00 (p=1.00).  
In men, the observed prevalence of pre-diabetes and T2DM was higher in Sami in all 
geographical regions; statistically significant ethnic difference was, however, only found for 
pre-diabetes in region 2 and for T2DM in region 3. In women, the observed prevalence of pre-
diabetes and T2DM was higher in Sami in all geographical regions but region 2, wherein 
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fewer Sami had dysglycaemia. Statistically significant ethnic differences were, however, only 
observed for pre-diabetes in region 1 and for T2DM in regions 1 and 3.  
 
3.3 Paper 3 
A total of 201 incident cases of DM were identified in the SAMINOR 2 Clinical Survey, 
based on self-report (n=138) or HbA1c≥6.5% (without self-report) (n=63). All who reported 
DM had HbA1c ≥ 6.5%. This number (n=201) corresponds to a 6.1% (95% CI: 5.3–6.9)       
8-year cumulative incidence of DM. No statistically significant difference in the 8-year 
cumulative incidence of DM was found between Sami and not-Sami of the same sex.  
The age-adjusted logistic regression analysis showed no statistically significant difference 
between Sami and non-Sami in the odds for DM in men or women. Further adjustments for 
other risk factors of DM confirmed that there were no ethnic differences in the odds of 
contracting DM. BMI, waist circumference (WC) and waist-to-height ratio (WHtR) were, 






4.1 Methodological considerations 
The first two articles had cross-sectional design, and the last one had a longitudinal design. 
Cross-sectional studies, which are conducted in a population at a specific time and place, 
measure disease frequency and factors which may cause diseases, or both, simultaneously 
[180]. The primary output of cross-sectional studies is prevalence data, although associations 
between risk factors and diseases can be sought and tested [180]. Cross-sectional studies 
usually serve as hypothesis-generating studies and inferring any causal relationship between 
the exposure and the outcome may be challenging, as the proper temporal sequence of events 
needed to establish causality cannot be observed due to the design of the study [180]. If a 
cross-sectional survey is followed up for a defined period of time to measure a health 
outcome, this study can then be a cohort study (longitudinal study) [180]. Paper 3 was a 
longitudinal study and tried to measure the cumulative incidence (risk) of DM. Similar to 
cross-sectional studies, longitudinal studies provide associations between risk factors and 
disease outcomes and inferring causal relationship between exposure and outcome may be 
problematic. Contrary to cross-sectional studies, in longitudinal studies risk factors are 
measured prior to the occurrence of the outcome, hence the risk of temporal bias (reverse 
causation) is reduced. It is unlikely that ethnicity, place of living, or education being affected 
by DM. However, it is possible that after a person is diagnosed with either pre-diabetes or 
DM, they apply lifestyle advices and change their dietary and physical activity habits. 
Furthermore, DM can lead to weight loss and in many instances, the only reason for seeking 
medical evaluation is unexplained weight loss. Consequently, BMI, WC, WHtR and physical 
activity are all subject to temporal bias in cross-sectional studies.  
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The ethnicity as an exposure variable in itself, is rarely a cause of a disease, but it is rather an 
index of some other related variables such as cultural (perception of illness and wellbeing), 
socioeconomic (education, profession, income), or lifestyle-related (diet, physical activity, 
smoking, alcohol drinking) factors [149]. The definition of ethnicity concept has always been 
a matter of contention, as ethnicity is a culturally constructed concept rather than being based 
on objective differences [181]. When it comes to Sami ethnicity in literature, there have been 
various definitions [177, 182, 183]. While some definitions pay especial attention to linguistic 
features [177], the core in the Sami definition in the present thesis is self-perception. 
According to the applied definition of Sami in this thesis, Sami is a person who responded 
that they either considered themselves to be Sami or reported to have a Sami ethnic 
background, and, in addition, at least one of their grandparents, parents, or they themselves 
spoke a Sami language at home. All participants who did not meet this criterion were defined 
as non-Sami. As many Sami people lost their Sami language during decades of assimilation 
and Norwegianisation policies, the linguistic features are not central in this definition. This 
definition is not mutually exclusive, which means that a Sami person may have a sense of 
self-affiliation to other ethnic groups as well as Sami ethnicity or speak other languages at 
home as well. The Sami features are regarded dominant in the present study. While an ethnic 
Norwegian person hardly presents affiliation to Sami ethnicity, it is likely that a Sami has a 
sense of affiliation to both Sami and Norwegian identity. It is the sense of belonging to an 
ethnic group that brings about behavioural and cultural differences and can expose a person 
for or protect them against health/disease determinants. As mentioned before, self-perception 
ethnicity is subject to change with time and some participants who considered themselves as 




As sensitive questions like those which may be construed as intrusive or invasive might 
produce lower participation rates, higher item non-response rates, or lower response accuracy 
[184], this was taken into account in the design and phrasing of the questions in the 
questionnaires. Cultural, social and historical attributes of the target society were also taken 
into consideration in the study design especially in the forming of questionnaires and during 
conduction of the surveys. To lessen the language barrier for Sami people, the questionnaires 
were provided in Sami languages, although only a few percent of Sami participants preferred 





Validity is the ultimate goal of any epidemiological study. Validity can be regarded as lack of 
bias and a study is called valid when it measures what it is supposed to measure correctly and 
without any distortion or deviation [185]. While internal validity indicates that the provided 
results are correct for the source population of the study sample, external validity ensures that 
the provided results are generalisable to other groups who were not included in the study 
[185]. There are two main types of errors, which can occur at virtually any step of the 
research process: systematic errors and random errors. While systematic errors, i.e. bias, 
affect comparison between groups, random errors affect the reliability (reproducibility) of the 
measurements and the precision of the estimates [186]. To control systematic errors, one 
should properly design the study, and to decrease random errors one could increase the 
sample size and apply good scientific techniques [186]. As error and bias cannot be fully 
controlled and avoided in epidemiological studies, the most important need is for systematic, 
cautious and critical interpretation of data and results [187]. 
Bias can create false patterns and misjudgements (either differences where none exist or 
failure to detect present differences) [187]. As mentioned above, to achieve high validity, one 
should avoid bias, which is categorised into three main types: selection bias, information bias, 





4.2.1 Selection bias 
Selection bias occurs when individuals have different probabilities of being included in the 
study groups according to relevant study characteristics, i.e. the exposure or outcome of 
interest [185]. This kind of bias creates erroneous prevalence estimates and distorted measure 
of association between exposure and outcome. As the included individuals are not 
representatives of the entire study population, the results are not generalisable to the study 
population or other groups [187].  
4.2.1.1 Paper 1  
Paper 1 is based on data from inhabitants of 24 municipalities included in the SAMINOR 1 
Survey. Having a 56% participation rate in the SAMINOR 1 Survey might be a source of 
selection bias. It is not certain that non-participants had the same characteristics as the 
participants. Participation rates were different from county to county and from municipality to 
municipality, which to some extent is due to different designs in the recruitment phase. For 
example, inhabitants of some municipalities received a reminder and non-responders got the 
chance to attend when the buses returned a couple of months later.  
Table 1 presents some characteristics of the invited, participants and working samples in 
paper 1 according to sex, age, regions, marital status, ethnicity, and education. The non-
participants tended to be men, young and single. In addition, there are numerous other 
important features of non-responders, which are not known to us. Therefore, it is not possible 
to rule out the possibility of selection bias. Lack of ethnic registry in Norway made it 
impossible to determine whether the ethnic composition of the participants in the SAMINOR 
surveys reflected that of the actual population in our geographical regions. The fact that the 
SAMINOR Study might have been deemed as being primarily directed towards Sami people 
might have deterred the non-Sami inhabitants of the included municipalities to participate in 
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the survey. On the other hand, the history of study misconduct and abuse of participants in so-
called scientific studies conducted throughout the periods when Sami people were regarded as 
an inferior race might be a source of concern and reluctance from Sami people to participate. 
As long as the participants in the survey are representatives of their respective ethnic groups, 
possible different participation rates in different ethnic groups would not affect the estimated 
prevalence of DM in each ethnic group and the odds ratio of DM. However, it might reduce 
the power of the study to show possible differences in the prevalence of DM. If participation 
rate, however, depends on both the exposure variable (ethnicity) and the outcome variable 
(DM), both the estimated prevalence of DM in each ethnic group and the odds ratio of DM 
would be distorted. In this case, the real prevalence of outcome variable (DM) in each ethnic 
group would also be a determinant of the total participation rate in that group.  
To enhance the participation rate, Sami people themselves were involved in almost all aspects 
of the SAMINOR Study and several information sessions were held in the municipalities 
before, during and after study performance. The participants were ensured that the 
questionnaires were anonymised and personal and sensitive information of participants were 
to be safeguarded. Participants were also ensured right to withdraw from the study at any 
given point of time.  
It is likely that those who are more conscious about their health (usually those with higher 
socioeconomic status) are more interested in participating in health studies like SAMINOR 
[189]. On the other hand, the severely ill and disabled may not be able to participate. This 
selection bias may lead to underestimation of the prevalence of DM.   
In spite of relatively large number of included municipalities (n=24) and participants, 




4.2.1.2 Paper 2 
Paper 2 is based on data from the SAMINOR 2 Clinical Survey. As participation rate here is 
just under 50%, the chance of selection bias due to non-response is even higher than in the 
SAMINOR 1 Survey. Table 2 presents some characteristics of the invited and participants in 
paper 2. Like in paper 1, non-participants tended to be younger and male. Apart from that, 
there is little information at hand regarding non-participants in our surveys. Similar to our 
survey, in the Tromsø 2 Study, it was reported that non-participants were over-represented 
among young unmarried men [190] with increased mortality rates [191]. Of the 50,807 invited 
in the HUNT 3 Study (2006–2008), 54% participated [189]; it was revealed that the 
prevalence of diseases like cardiovascular diseases, DM, and psychiatric disorders was higher 
among non-participants. In addition, registry data revealed that the non-participants had lower 
socioeconomic status and higher mortality rate [189]. If this was the case in our surveys, it 
can be assumed that the prevalence of T2DM is underestimated. Nonetheless, it is not known 
if non-participation due to the mentioned factors affected Sami and non-Sami subjects equally 
or not. Selection bias due to non-participation is in most cases a greater threat to the validity 
of prevalence estimates than to the validity of the associations between exposure and outcome 
[192]. 
As the number of included municipalities in the SAMINOR 2 Clinical Survey was limited 
(n=10), the participants may be considered representative for the rural, Sami and non-Sami 
population in included municipalities in Finnmark and Troms counties. However, 
generalisations to the entire Sami or non-Sami populations in Norway are not advised.   
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4.2.1.3 Paper 3 
This paper is a longitudinal study following participants in the SAMINOR 1 Survey up to the 
SAMINOR 2 Clinical Survey. From the 10 municipalities, which were included in the 
SAMINOR 1 Survey, 5875 participants could potentially be followed up to the SAMINOR 2 
Clinical Survey. Of 5875 eligible individuals, 3303 (56.2%) were included in the analyses 
(Figure 8). Dropouts might be due to death, emigration, debilitating diseases, or conscious 
choice not to participate in the follow-up study. Loss-to-follow-up (attrition or censoring) is a 
source of selection bias if those who were eligible to participate in the SAMINOR 2 Clinical 
Survey but did not do so had different risk profile than those who participated in the 
SAMINOR 2 Clinical Survey. In fact, loss-to-follow-up should be independent of the 
outcome [185].  
Table 4 presents some characteristics of individuals we were able to follow-up compared to 
those who were not followed up. Although some differences in the marital status, smoking, 
mental health score, yearly gross income of the household and leisure-time physical activity 
were found between the two groups, main risk factors for DM including age, obesity indices 
(BMI, WC, and WHtR) and family history of DM were not markedly different.  
Linkage of data from the SAMINOR 1 Survey and the SAMINOR 2 Clinical Survey was 
done only for those who participated in both surveys and gave consent to linkage, so it was 
not feasible to keep track of those who were censored during the follow-up. Our dataset was 
not linked to the Cause of Death registry, so we do not have direct information about the 
number and death cause of those who died during the follow-up period. We do not expect that 
there were many participants who got DM during the follow-up period and died of the disease 
itself or its late complications.   
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Table 4. Characteristics of individuals we were able to follow-up compared to those who were not followed up 
among those who participated in SAMINOR 1 (2003–2004) and were eligible1 for SAMINOR 2 (2012–2014), by 
sex (N=5875). Numbers are mean (standard deviation) for continuous variables (age, body mass index, waist 
circumference, and waist-to-height ratio) and percent (number of subjects) for categorical variables (family history 
of DM, married, education>12 years, SCL-10 score>1.85, alcohol, low-income, and inactive). 
 Included in the  
follow-up analysis 
Not followed up p-value 
Men N=1447 N=1307  
Age (year) 52.4 (8.7) 51.2 (9.8) <0.01 
Body mass index (kg/m2) 27.5 (3.5) 27.6 (4.2) 0.42 
Waist circumference (cm) 92.3 (9.3) 93.0 (10.9) 0.07 
Waist-to-height ratio 0.534 (0.054) 0.537 (0.064) 0.10 
Sami ethnicity (%) 40.2 (581) 32.7 (866) <0.01 
Family history of DM2 (%) 19.4 (280) 18.2 (238) 0.44 
Married3 (%) 64.5 (933) 52.8 (690) <0.01 
Education>12 years (%) 32.8 (458) 30.7 (381) 0.26 
SCL-10 score4 >1.85 (%) 5.3 (72) 9.5 (114) <0.01 
Current smoker5 (%) 28.8 (416) 39.5 (516) <0.01 
Alcohol6 (%) 30.7 (444) 31.1 (407) 0.80 
Low-income7 (%) 57.0 (825) 61.5 (804) 0.02 
Inactive8 (%) 18.8 (272) 23.1 (302) 0.01 
    
Women N=1856 N=1265  
Age (year) 51.6 (9.0) 50.7 (10.1) <0.01 
Body mass index (kg/m2) 27.4 (4.6) 27.6 (4.9) 0.38 
Waist circumference (cm) 84.0 (11.2) 84.2 (11.8) 0.08 
Waist-to-height ratio 0.526 (0.074) 0.527 (0.076) 0.40 
Sami ethnicity (%) 39.5 (733) 29.4 (372) <0.01 
Family history of DM2 (%) 23.2 (430) 21.8 (276) 0.38 
Married3 (%) 66.0 (1225) 58.2 (736) <0.01 
Education>12 years (%) 38.0 (674) 36.3 (428) 0.34 
SCL-10 score4 >1.85 (%) 8.4 (141) 11.5 (130) <0.01 
Current smoker5 (%) 30.6 (568) 40.9 (517) <0.01 
Alcohol6 (%) 19.7 (365) 20.5 (259) 0.58 
Low-income7 (%) 58.7 (1090) 62.7 (793) 0.03 
Inactive8 (%) 19.1 (355) 22.9 (289) 0.01 
1) Living in the 10 SAMINOR 2 municipalities at time of SAMINOR 1 with relevant year of birth 
2) Those who had at least one with DM among father, mother, siblings or children 
3) Married vs single, widow/widower, divorced, or separated 
4) SCL-10 score: Hopkins symptom checklist score 
5) Current smokers vs former smokers or never-smokers 
6) Drinking alcohol at least once a week 
7) Yearly gross income of the household less than 451,000 Norwegian Kroner 






If loss-to-follow happened due to diseases, which share risk factors with the outcome of 
interest (like cardiovascular diseases and DM), the risk of DM would be underestimated 
(competing risks). Cardiovascular diseases can be a complication of DM, but there is not a 
one-to-one correspondence between cardiovascular diseases and DM. In fact, most cases of 
cardiovascular diseases occur independently of DM and not all who get DM die of 
cardiovascular diseases. According to the Norwegian Institute of Public Health, cancers, not 
cardiovascular diseases, are the leading cause of death in people with similar age-span as our 
participants [193]. Based on numbers from Statistics Norway, one can expect around 330 
deaths from year 2001 until 2010 (10 years) in a group of 5875 individuals with similar age-
span and age-distribution as our participants (calculations not shown) [194]. Competing risks 
become more important with the increasing age of the population under study (increased risk 
of multimorbidity). As the mean baseline age of both those who were followed up and those 
who were not was around 52 years, and there were relatively few expected deaths (a total of 
330 deaths), it is not expected that competing risks have substantially affected our estimate of 
the cumulative incidence of DM. Furthermore, studies have shown minimal or no difference 
between Sami and non-Sami individuals in the distribution of risk factors for cardiovascular 
diseases and/or the risk of acute myocardial infarction or cerebral stroke; hence, the relative 
risk of DM (between Sami and non-Sami) was also not considerably distorted [141, 195].  
In Kautokeino and Karasjok, where a large share of the population is involved with reindeer 
husbandry, the SAMINOR Clinical Survey was conducted in winter-time, to avoid seasons 
when many Sami people would be out of their main living place due to reindeer husbandry. 
We do not have information on the participants in the SAMINOR 1 Survey, who due to 
moving to other regions, were not included in the final analysis, but they are expected to be 
few, and it is unlikely that they had any impact on the conclusions. 
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4.2.2 Information bias  
Information bias (e.g., measurement error) occurs when information collected about and from 
study subjects is erroneous [185]. This type of bias leads to a person or population subgroup 
being put into the wrong category (misclassification) [187]. When the misclassification is 
random and independent of any other variable, it is called non-differential misclassification. 
When the mismeasurement (error) affects subgroups unequally, it is called differential 
misclassification [187]. Put in other words, when misclassification in the outcome variable 
depends on the exposure status or vice versa, the misclassification is differential [186].  
Recall bias resulting from inaccurate recall of past events is a common source of 
misclassification in cross-sectional and case-control studies. This bias (differential 
misclassification) occurs as comparison populations or subgroups (e.g. diseased individuals) 
unequally recall and report outcome-related events and/or exposure to various risk factors 
[186].  
Ethnicity was the exposure variable (or proxy of exposure) throughout the thesis and is more 
likely to be wrongly reported by Sami people than non-Sami. Reporting Sami ethnicity needs 
more conscious choice than reporting Norwegian ethnicity and the majority of people regard 
Norwegian as the default ethnicity. A Sami person might intentionally or unintentionally 
report his/her ethnicity as Norwegian. Intentional misreporting happens if the person has a 
sense of inferiority by being identified as Sami and it is not unimaginable taking the long 
history of stigmatisation and assimilation of Sami people into consideration. Unintentional 
misreporting of Sami ethnicity by a Sami person can occur if the person is not aware that they 
had a Sami-speaking grandparent or parent or they had a Sami ethnic background. Some Sami 
people might have misunderstood the question “What do you consider yourself to be?” as a 
question about their citizenship and in spite of answering positively to all other questions 
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regarding the Sami ethnicity, they reported that they considered themselves as Norwegians. 
Although according to our definition of Sami ethnicity, this person was regarded as Sami, if 
other answers were also erroneous, the person would not be categorised as Sami. As 
mentioned before, a high agreement was observed between Sami ethnicity classifications in 
the SAMINOR 1 and the SAMINOR 2 Clinical surveys.  
We have to assume that misclassification in the exposure variable (ethnicity) does not depend 
on the outcome variable status (like e.g., dysglycaemia), therefore the misclassification is 
non-differential. As alternative definitions of Sami ethnicity produced quite similar results 
(results not shown) and considering that the participants were provided with comprehensive 
instructions regarding the meaning of questions and how to fill out the questionnaires, we do 
not think that this misclassification was of great importance in the present thesis. 
DM in most situations is a chronic and life-long disease without a cure (except gestational 
diabetes). Contrary to T1DM where the patient would not survive without diagnosis and 
treatment, there are always a proportion of those with T2DM who are not aware of their 
disease and consequently do not report it in the questionnaires. As well as the disease itself, 
related details like the exact date of diagnosis, type of DM (especially gestational diabetes), 
medications (if prescribed), family history of DM, or risk factors for T2DM (e.g. unhealthy 
diet, low physical activity) might be reported imprecisely. A qualitative study argued that 
Sami people tend to underreport their diseases due to some cultural differences (different 
conceptualisation of diseases) [196]. If this was the case for our Sami participants, this might 
have led to underestimation of the prevalence of DM among them (differential 
misclassification).  
As mentioned previously, the questionnaires were in some municipalities available in both 
Norwegian and Sami languages, and people in the age group 70–79 years were given 
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questionnaires with fewer questions and larger font size. Nonetheless, there are many elderly 
Sami who have difficulty reading and writing both Norwegian and Sami. In both the 
SAMINOR 1 and the SAMINOR 2 Clinical surveys, participants were offered help in filling 
out the questionnaire if they requested. Therefore, the probability of misclassification due to 
linguistic issues is negligible.  
The validity of the questionnaires in the SAMINOR 1 and SAMINOR 2 Clinical surveys was 
not assessed, but according to literature, questionnaires are a valid and reliable source of 
acquiring information about prevalent, known cases of DM. According to the first HUNT 
Study performed in North Trøndelag, Norway, the sensitivity and PPV of applied 
questionnaire for self-reported DM were 99.4% and 96.4%, respectively [197]. A Dutch study 
reported no ethnic difference in the accuracy of self-reported DM when comparing Dutch 
patients with patients who were first-generation immigrants, mostly from Turkey and 
Surinam [198]. In a study conducted in Olmsted county, Minnesota, with 2037 participants 
aged ≥ 45 years, the sensitivity and PPV of self-reported DM were 66.0% and 94.3%, 
respectively [199]. The French national study of CADEUS reported a sensitivity and PPV of 
self-reported DM as 86.7% and 73.4%, respectively [32]. The Finnmark study, which applied 
a quite similar questionnaire to the questionnaire applied in our surveys, reported 66% 
agreement between positive answers to DM and medical records [200]. Of 33 participants 
who had reported DM at Finnmark 1 Study, 24 (73%) did so at Finnmark 2 Study conducted 
three years later. The test-retest reliability of self-reported T1DM and T2DM diagnoses was 
assessed between three self-administered questionnaires applied in Norwegian Women and 
Cancer Study (the NOWAC Study). According to the authors, the Cohen’s kappa for T1DM 
was ≥ 0.73 in the 1991–2005 and the 1998–2005 test–retest studies, and 0.83 in the 1991–
1998 test–retest study [201]. The kappa for T2DM was reported moderate (0.57) in the 1991–
2005 test–retest study and high (≥0.66) in the 1991–1998 and 1998–2005 test–retest studies 
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[201]. All the above-mentioned studies applied medical records as reference standard. The 
validity of a questionnaire might vary from population to population and factors like age, 
education level, and health status of participants as well as phrasing of the question(s) might 
affect the performance of a given questionnaire. As mentioned before, the two main questions 
regarding DM were not identical in the SAMINOR 1 and the SAMINOR 2 Clinical surveys. 
Contrary to the SAMINOR 1 Survey, the question about DM was followed by questions 
about the type of DM in the SAMINOR 2 Clinical Survey. Furthermore, in the SAMINOR 2 
Clinical Survey, “elevated blood sugar levels” was added in parentheses. This may have lead 
to more people answering “yes” to the question. This may render a different validity for both 
questionnaires.   
Non-differential misclassification is more subtle and may have little or no effect on the final 
prevalence figure [187]. If non-differential misclassification is present when relating the 
(dichotomous) outcome of interest (DM in the present thesis) and the (dichotomous) exposure 
variable (ethnicity in the present thesis), the strength of association is always underestimated, 
so the problem is failing to find associations, which, in reality, are present [186, 187]. 
Misclassifications that affect confounding factors tend to have unpredictable effects [187].  
The misclassification of ethnicity (the same definition in all papers) and self-reported DM is 
already discussed; thus in the rest of this section, misclassification of dysglycaemia (pre-
diabetes and/or diabetes mellitus) will be discussed under the respective papers.  
4.2.2.1 Paper 1  
In paper 1, random plasma glucose (RPG) with cut-off 7.8 mmol/L and 11.1 mmol/L was 
used to categorise pre-diabetes and DM, respectively. Random plasma glucose in the presence 
of classic symptoms of hyperglycaemia or hyperglycaemic crisis is recommended by the 
ADA for diagnosis of DM [3]. In the SAMINOR Study, we did not perform medical 
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examination to find DM symptoms, so we relied on RPG values without knowing about 
classical DM symptoms to recognise DM. Neither did we carry out OGTT test, so we used 
RPG values (7.8–11.0 mmol/L) instead of 2hpp test results to categorise pre-diabetes.  
The RPG levels are affected by the natural fluctuations of blood glucose throughout the day 
and the mentioned criterion can only detect DM that is poorly controlled [202]. Paper 1 used 
data from 24 municipalities included in the SAMINOR 1 Survey. In the SAMINOR 1 Survey 
neither other laboratory tests (e.g. fasting plasma glucose, 2hpp [glucose tolerance test] or 
HbA1c) nor medical examination was used to ascertain DM. The applied cut-offs have very 
low sensitivity to identify pre-diabetes and DM [86]. This is reflected in the low percentage of 
diagnosed cases using this cut-off (only 8.6% of all ascertained DM cases). Furthermore, the 
overall prevalence of pre-diabetes and DM was reported as 2.8% and 4.6%, respectively. We 
assume that the real prevalence of pre-diabetes and DM was underestimated in paper 1. In this 
paper, no overall difference in the prevalence of pre-diabetes and DM was found between 
Sami and non-Sami of the same sex. As mentioned before, non-differential misclassification 
in the outcome variable inevitably attenuates the strength of association between the exposure 
and the outcome [187]. Although same RPG cut-offs were applied to both ethnic groups, we 
cannot rule out any ethnic difference in the prevalence of pre-diabetes and/or DM in the entire 
survey region.  
4.2.2.2 Paper 2  
The choice of HbA1c cut-off of 6.5% was based on recommendation from the ADA [3] and 
Norwegian medical guidelines [81]. Numerous publications have reported different 
performance of HbA1c at different cut-offs [34, 96-98, 203-206]. According to the Tromsø 
OGTT Study, HbA1c cut-off at 6.5% gives a sensitivity and PPV of 34.7% and 41.2%, 
respectively (OGTT as reference test, prevalence=5.7%) [96]. It is worth mentioning that 
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there is no perfect test (gold standard) for diagnosing DM and each test has its strengths and 
limitations and can capture different groups of patients [101]. Although the mentioned 
sensitivity and PPV could yield a comparable number of false positive and false negative 
cases, which could compensate for each other to give a realistic prevalence of DM, the 
relatively low sensitivity and PPV lead to a large misclassification of T2DM. This 
misclassification is non-differential as it affects both ethnic groups equally. Nonetheless, as 
mentioned before, any non-differential misclassification in the outcome variable attenuates 
the strength of association between exposure (ethnicity) and outcome (T2DM). Despite the 
misclassification, a statistically significant ethnic difference in the prevalence of pre-diabetes 
and T2DM was observed in paper 2. It implies that the real ethnic difference in the prevalence 
of pre-diabetes and T2DM might be larger than what was observed. The same applies to other 
risk factors for T2DM like male sex, (general and abdominal) obesity, low education and low 
physical activity. The non-differential misclassification in the outcome variable might have 
diluted the association between each risk factor and the outcome so that the OR is 
underestimated and no longer statistically significant. Of the mentioned risk factor variables, 
misclassification was more likely to affect physical activity, as it was not measured 
objectively. It is not clear if the misclassification in physical activity was differential or non-
differential. As mentioned before, misclassification in the confounding variable may have 
unpredictable effect on the measure of association between exposure and outcome [187]. 
Another source of (non-differential) misclassification in this paper was that all those who had 
HbA1c ≥ 6.5% (without mentioning T2DM in the questionnaire) were classified as having 
T2DM. New research have shown that a considerable proportion (approximately 10–15%) of 
those who get DM in adulthood and were previously diagnosed as T2DM have indeed Latent 
Autoimmune Diabetes of Adults (LADA) [207]. 
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Unlike paper 1, Sami people had higher prevalence of pre-diabetes and T2DM in the majority 
of geographical regions (stratified by sex) in paper 2. This makes it less likely that the 
observed ethnic difference is a chance finding. Furthermore, regarding the non-differential 
misclassification in the outcome variable, it is more likely that the real ethnic differences were 
even larger than what was observed. As for paper 1, the relatively small number of 
participants in each geographical region should be taken into account before making any 
inference in this regard.  
4.2.2.3 Paper 3 
The same criterion for categorisation of incident cases of DM was used in this paper (self-
report and/or HbA1c ≥ 6.5%) as in paper 2; thus the same issues with non-differential 
misclassification of DM cases due to low sensitivity and PPV of HbA1c test affect the 
strength of association between the exposure and outcome. Another source of 
misclassification is to classify prevalent cases of DM as the incident ones. We excluded those 
who reported the time of DM diagnosis during the first two years of follow-up after the 
SAMINOR 1 Survey (two years wash-out period). Nevertheless, regarding the low sensitivity 
of RPG ≥ 11.1 mmol/L to ascertain those with DM, there is still possibility that some 
prevalent cases of DM were classified as incident cases of DM.  
Besides small sample size, the expected non-differential misclassification in the outcome 
(DM) variable (as well as in the exposure variable) might be possible explanations for lack of 




4.2.3 Confounding, over-adjustment, and residual confounding  
The term confounding refers to a situation in which a non-causal association between a given 
exposure and an outcome is observed due to the impact of a third variable (or group of 
variables), usually known as confounding variable(s) [208]. The confounder is defined as a 
variable, which is causally associated to the outcome and causally or non-causally associated 
with the exposure, but is not part of the causal pathway between the exposure and the 
outcome (intermediate variable) [208]. The potential for confounding is present whenever the 
cardinal rule “compare like-with-like” is broken [187]. Put in other words, when the 
comparison groups differ in characteristics other than the risk factor under study [187]. 
Confounding is of particular importance in differentiating between causal and non-causal 
(pure association) relations [187]. The confounding effect can be controlled for through 
various ways like randomisation (randomised controlled trials), matching (case-control 
studies), selecting comparable groups or restriction entry into study (e.g. same sex, age or 
socioeconomic status), stratification (e.g. by sex or age), adjustment (multiple regression 
analyses) and standardisation (directly or indirectly) [187].  
In dealing with confounders, one should be aware of two pitfalls; over-adjustment and 
residual confounding. Over-adjustment occurs when adjustment is inadvertently carried out 
for a variable that either lies in the causal pathway between the exposure and the outcome or 
is so strongly related to either the exposure or the outcome that their true relation is distorted 
[209]. Over-adjustment may obscure a true effect or create an apparent effect which does not 
exist [210].  
Residual confounding occurs when adjustment does not completely remove the confounding 
effect due to a given variable or set of variables [211]. The common sources of residual 
confounding are [211]: 
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1) Improper definition of the categories of the confounding variable 
2) The variable used for adjustment is an imperfect marker of the condition or 
characteristic the investigator wishes to adjust for 
3) Failure to adjust for other important confounders 
4) Misclassification of confounding variable 
4.2.3.1 Paper 1 
Stratified by sex, we compared Sami and non-Sami aged 36–79 years inhabiting the same 
rural districts of Northern and Mid-Norway. The principle of comparing comparable people 
with each other is the cornerstone of the study design (the SAMINOR Study) and applies to 
all the papers. The total prevalence of pre-diabetes and DM among Sami and non-Sami men 
and women were age-standardised using European standard population of 2013. All analyses 
were stratified by sex and adjusted for age in the multinomial logistic regression analysis as 
sex and age are two known confounding factors. There were other important confounding 
variables, which were not adjusted for in the multinomial logistic regression, as they had not 
been measured precisely. Dietary habits and physical activity, for example, are very hard to 
objectively and precisely measure especially in the years prior to the DM diagnosis. 
Education is usually used in studies as a proxy for socioeconomic status, but education is not 
a perfect surrogate for socioeconomic status and was not considerably different between the 
two ethnic groups. Temporal bias was a great obstacle in this regard, as DM occurrence could 
negatively affect the income and physical activity of a person. Although weight and height (to 
measure BMI, WC and WHtR) had been objectively and reliably measured, they were not 
adjusted for in the multinomial logistic regression analysis as it was argued that DM and 
obesity were firmly related together and both were parts of metabolic syndrome. Occurrence 
of T2DM may affect obesity either through insulin resistance and resultant weight loss or 
through conscious changes in lifestyle. This may lead to temporal bias assessing the effect of 
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obesity on the development of T2DM. Furthermore, it was argued that obesity was on the 
causal pathway to DM (intermediate variable). Nonetheless, it may be argued that obesity 
should have been accounted for owing to the fact that it is a source of residual confounding. 
Obesity is neither a necessary nor a sufficient cause of DM and by adjustment for it, one can 
assess the effect of the exposure on the outcome which goes through obesity.  
4.2.3.2 Paper 2 
Participants were 40–79 years old inhabitants of 10 rural municipalities in Northern Norway. 
Age-standardisation of the prevalence values of pre-diabetes and T2DM was carried out based 
on the invited individuals in the SAMINOR 2 Clinical Survey. Prevalence values and 
analyses were all stratified by sex. In the multinomial logistic regression analysis age, 
education, BMI, WHtR and physical activity were adjusted for. Physical activity was self-
scored from 1 to 10 and as this scoring was subjective, there is possibility of misclassification 
and residual confounding. As discussed before, education is not a perfect surrogate for 
socioeconomic status. The possibility of residual confounding cannot be ruled out as other 
potential confounding factors (like dietary habits) might have been overlooked. Although 
hypertension, hypertriglyceridemia, low HDL cholesterol are known risk factors for T2DM 
[33], they were not adjusted for in the regression analysis to avoid over-adjustment. These 
risk factors are firmly related to T2DM and are all part of metabolic syndrome [212]. As DM 
and family history for DM in an individual are firmly related to each other, adjustment was 




4.2.3.3 Paper 3 
Participants are 30 and 36–71 years old inhabitants of 10 rural municipalities in Northern 
Norway. All analyses were stratified by sex. The 8-year cumulative incidence is presented 
separately for men and women, and the older and younger age groups. In the logistic 
regression analysis, age, ethnicity, BMI, WC, WHtR, education, leisure-time physical 
activity, mental distress score, smoking, and alcohol drinking were adjusted for. These 
variables were measured in the SAMINOR 1 Survey (prior to development of diabetes 
mellitus) so the risk of temporal bias is reduced. The validity of the applied questions about 
leisure-time physical activity has been assessed in several studies and is shown to be good 
[213, 214], nevertheless, there is inevitable misclassification in the reported leisure-time 
physical activity. In the final analysis, this variable was dichotomised into low leisure-time 
physical activity (reading, watching TV or other sedentary activities) versus higher leisure-
time physical activity. Smoking (current smoker vs ex-smoker or never-smoker), alcohol 
drinking (at least once a week versus lower or no alcohol drinking) and mental distress 
(Hopkins SCL-10 >1.85 versus others) were also used as dichotomous variables which opens 
the possibility for residual confounding. It is worth mentioning that the effects of the above-
mentioned dichotomised variables were assessed separately and as original multi-categorical 




4.3 Interaction  
Interaction (effect modification) is present when two or more risk factors modify the effect of 
each other with regard to the occurrence or level of a given outcome [215]. Put in other 
words, interaction occurs when the effect of a risk factor A on the risk of an outcome Y is not 
homogeneous in strata formed by a third variable Z [215]. To assess the interaction, one can 
either examine the interaction term in the regression analysis or stratify the population 
according to the potential effect modifier. Interaction is present if the interaction term in the 
logistic regression is statistically significant or the measure of risk is heterogeneous within the 
strata formed by the potential effect modifier [215]. In papers 1 and 2, there was observed a 
heterogeneity of risk between different geographical regions. According to the above 
definition, there is an interaction by geographical region when assessing the relation between 
ethnicity and the prevalence of pre-diabetes or DM.  
4.4 External validity 
Most of our study participants were inhabitants of rural municipalities and districts in 
Northern and Mid-Norway, all of which have substantial Sami settlements. We believe that 
the results from paper 1 can be generalised to the Sami and non-Sami people living in rural, 
Sami core areas in these regions. Generalisation to other Sami or non-Sami people living in 
urban areas or rural areas in other parts of Norway may be problematic. Results in paper 2 and 
3 are based on data from only ten municipalities all located in Northern Norway. As there 
might be considerable differences in the living conditions of inhabitants of the ten 
municipalities and other municipalities and given the small number of included municipalities 
and participants, generalisation of the results from papers 2 and 3 to other regions might be 
even more problematic. The different geographic areas and population composition must be 
taken into account when comparing results from paper 1 and 2.  
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4.5 Statistical associations 
The SAMINOR 1 Survey had a large sample size (n=16,538 after exclusion of 30-year-old 
participants). Large sample size increases the power of the study and the precision of the 
estimates. Paper 1, which was based on a large sample, had potential to detect small ethnic 
differences in the prevalence of pre-diabetes and DM.  
The SAMINOR 2 Clinical Survey had considerably smaller sample size (n=6004); hence 
paper 2, which was based on the data obtained from this survey suffer from lower power and 
precision. Paper 3 had even smaller sample size (n=3303), and the study’s power to catch any 
ethnic difference in the cumulative incidence of DM was not high. The large within-group 
variations worsened the issue.   
The comparisons, which were made in rather small geographical regions or sex and age 
groups all suffer from having small sample size with low power and precision. 
It is of particular importance that both Sami and non-Sami people represent a wide variety of 
life and are under constant effect of genetic and environmental factors. They comprise 
heterogeneous and dynamic populations and this heterogeneity was best echoed in the varying 
prevalence of pre-diabetes and DM in different sex and age groups residing in different 
geographical regions. Even municipalities, which were put into one geographical region (like 




4.6 Brief discussion of main results and future research 
In paper 1, we found no overall ethnic difference in the prevalence of pre-diabetes and DM. 
Nonetheless, there were some disparities in the prevalence of pre-diabetes and/or DM in some 
geographical regions. In spite of the large sample size of the SAMINOR 1 Survey, the use of 
RPG (≥11.1 mmol/L) lowered the ability of the study to catch undiagnosed cases of DM. 
While according to our definition of DM in paper 1 only about 8% of cases were previously 
undiagnosed, it is reported in a systematic review that globally, undiagnosed adult DM cases 
ranges from 24.1% to 75.1% across data regions [110]. The low sensitivity of our method to 
catch DM cases might have led to underestimated absolute prevalence of pre-diabetes and 
DM as well as failure to find any ethnic difference in the prevalence of pre-diabetes and/or 
DM.  
In paper 2, a combination of self-report and HbA1c ≥ 6.5% was used to ascertain DM. It is 
known that HbA1c with this cut-off has generally low sensitivity and identifies one-third 
fewer cases of undiagnosed DM than a fasting glucose cut-off of ≥ 7.0 mmol/L [3]. In spite of 
this low sensitivity, the total age-standardised prevalence of pre-diabetes and T2DM was 
respectively 34.1% and 8.7%. According to these findings, more than one-third of the 
participants had pre-diabetes and run a substantial risk of developing T2DM later in life. 
Furthermore, the prevalence of both pre-diabetes and T2DM was statistically significantly 
higher among Sami compared with non-Sami. This pattern was present in almost all age and 
sex groups and geographical regions. Although the prevalence of pre-diabetes and T2DM was 
shown to be higher among Sami participants compared with their non-Sami counterparts, the 
95% CIs around the odds ratios were quite wide. This reflects the uncertainty around the exact 
amount of the higher odds of having the disease and can be due to our relatively small sample 
size.   
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The higher estimated prevalence values of pre-diabetes and T2DM in the SAMINOR 2 
Clinical Survey compared to corresponding values in the SAMINOR 1 Survey can partly be 
explained by the higher mean age of participants in the SAMINOR 2 Clinical Survey. The 
questions regarding DM was not identical in the two surveys and the question in the 
SAMINOR 2 Clinical Survey was followed by questions on the type of DM. Applying 
different methodology (HbA1c ≥ 6.5% vs RPG ≥ 11.1 mmol/L) is another important 
explanation for the observed difference in the estimated prevalence values. Nevertheless, it is 
quite likely that the prevalence of pre-diabetes and DM in the included municipalities 
increased during this period in harmony with the increase in the prevalence of DM in all 
Norway [10]. 
The most plausible explanation for the observed higher prevalence of pre-diabetes and T2DM 
in Sami subjects was higher WHtR (index of abdominal obesity). In the SAMINOR 2 Clinical 
Survey, WHtR was higher among both Sami men and women compared with their non-Sami 
counterparts. WHtR has in several studies been mentioned to be the best indicator of obesity 
and predictor of metabolic syndrome and cardiovascular diseases [216]. As Sami people are 
in average 5–6 cm shorter in stature than their non-Sami counterparts, WC does not seem to 
perform satisfactorily in comparison of abdominal obesity between them. Obesity was also 
more prevalent among Sami participants of both sexes in the SAMINOR 1 Survey [13, 44]. 
Obesity in combination with low physical activity (which was also reported by the Sami 
women) are well-established risk factors for T2DM.  It has been reported that the prevalence 
of metabolic syndrome (hyperglycaemia, hypertension, obesity, hypertriglyceridemia, low 
HDL cholesterol) among participants of both ethnicities in the SAMINOR 1 Survey was quite 
high [13]. Hansen, in his study on the Sami populations ascribed a number of poor health 
outcomes like obesity, metabolic syndrome and DM to ethnic discrimination reported by 
Sami people in the SAMINOR 1 Survey [167]. In spite of revitalisation and integration of 
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Sami culture, language and identity, the Sami people still report ethnic discrimination more 
frequently than do ethnic Norwegians [217]. Experienced ethnic discrimination has been 
reported to be associated with adverse somatic and psychological health outcomes [218, 219], 
and this relationship is complex and multidimensional [220]. This association is usually 
stronger in areas where Sami populations live in minority compared to areas they live in 
majority [167]. As DM is known to be a chronic and multifactorial disease, it is more likely 
that various behavioral, environmental, biological and genetic factors to varying extent 
interact with stressful conditions like perceived discrimination and contribute to illness and 
early mortality [221]. 
Although no statistically significant difference in the 8-year cumulative incidence of DM was 
observed (paper 3), this lack of statistically significant difference can partly be explained by 
the small sample size. As for paper 2, indices of obesity (e.g. BMI and WHtR) were generally 
higher among Sami compared to their non-Sami counterparts. 
Contrary to many indigenous peoples throughout the world, no huge difference in the 
prevalence or incidence of DM was observed between Sami people and ethnic Norwegians. 
This can be explained by the close interaction and similar standard of living between them. 
The rapid transition from traditional to so-called western and sedentary lifestyle has affected 





5 Implications for public health policies 
High prevalence of pre-diabetes and DM among both Sami and non-Sami people and the 
observed higher prevalence of pre-diabetes and T2DM among Sami compared to non-Sami 
(in the SAMINOR 2 Clinical Survey) needs attention from health authorities and policy-
makers. A large proportion of both Sami and non-Sami people had high indices of obesity and 
obesity was the most plausible explanation for higher prevalence of pre-diabetes and T2DM 
among Sami people. These results were partly observed in previous studies as well [222]. The 
fact that more than one-third of inhabitants in the included municipalities suffer from pre-
diabetes and run a higher risk of developing T2DM in the future underscores the need for 
promoting information campaigns to enhance inhabitants’ insight into lifestyle-related 
diseases and potential consequences of obesity and T2DM. Primary health care personnel 
especially general practitioners have decisive roles in changing patients’ health attitude and 
implementing preventive measures. Encouraging walking and daily physical activities, 
promotion of dietary balance in macronutrient intake, increasing fruit and vegetable 
consumption, reduction in high-sugar and fast-food intake, motivating people in consuming 
traditional food sources are examples of the preventive measures in this regard [223]. In 
tailoring any health promotion scheme, Sami language, culture, and perspectives should be 
taken into account. At-risk persons like those with family history of DM, personal history of 
gestational diabetes, IFG, IGT, high BMI or WC, hypertension or dyslipidemia should be 
encouraged to attend periodic medical encounters to diagnose any dysglycaemia at early stage 
and prevent T2DM development towards late complications. Vigorous efforts have so far 
been made by Centre for Sami Health Research to convey the findings of the SAMINOR 
Study to the inhabitants and health care providers of the included municipalities (at local 
level) and to draw health policy-makers’ attention to the needs of local communities (at 
national level).   
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6 Further research 
Follow-up studies in the future with especial emphasis on the risk factors of T2DM should be 
undertaken. The applied questionnaires should be validated in advance by comparison 
between the answers to the questions and medical records. The main concern regarding DM is 
its late complications (rather than hyperglycaemia itself) and these complications develop 
well below recommended medical cut-offs [3]. The main objective in most epidemiological 
studies is to measure the burden of diseases, their risk factors and consequences rather than 
diagnosing unknown cases. Therefore, instead of or besides using a certain cut-off for the 
applied test to dichotomise participants as having or not having DM, a risk score can be 
developed and calculated for each participant based on the continuum of risk at various test 
values. Sum of these scores can then be compared between the ethnic groups.  
Norway has comprehensive registries and healthcare databases like the Norwegian 
Prescription Database, the Norwegian Patient Registry and primary care database. The future 
surveys of the SAMINOR Study can benefit from linkage of participants’ data to these 
databases. To elucidate the role of genetic endowment in predisposition to and development 
of various diseases, gene analyses can be included in the future studies.   
As obesity is highly prevalent amongst both Sami and non-Sami people and seems to be the 
most plausible cause of higher prevalence of T2DM among the Sami people, any future study 
should try to measure thoroughly the obesity indices. Beside traditional anthropometric 
measures (e.g. BMI, WC, WHtR), new techniques for measuring body composition (e.g. 
bioelectrical impedance, dual-energy X-ray absorptiometry, body density, and total body 
water estimates), physical activity and calorie expenditure should be applied. Potential risk 
factors for obesity like genetic predisposition, unhealthy dietary habits, low physical activity, 
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Helsedepartementet har bedt oss undersøke helse- og levekårsforhold hos alle født
i 1925–1967 og i 1973 i utvalgte kommuner med samisk og norsk bosetting i
Nord-Norge og Nord-Trøndelag. Formålet er å innhente opplysninger om hjerte- og
karsykdommer, kreft, allergier, smerter og andre lidelser samt ulykker for å kunne
forebygge dem. Videre er målet å få et bilde av folks oppfatning av helsetjenestetil-
budet, deres levesett slik som kosthold og røyking, levekår og tilhørighet. De som
ønsker å delta, blir med i et forskningsprosjekt som består av spørreskjemaer og
helseundersøkelse. Alle opplysninger fra undersøkelsen vil bli behandlet konfiden-
sielt.
Helse- og levekårsundersøkelsen er nærmere beskrevet i brosjyren, som ligger ved-
lagt. Dersom du er i tvil om noe, kan du kontakte oss på tlf. 78 46 89 04 eller på
e-post: helseus@fagmed.uit.no
Du kan delta  på følgende måter: (kryss av øverst på spørreskjema under «samtyk-
ke til deltakelse»)
A Dersom du ønsker å delta i helseundersøkelsen og forskningsprosjektet, krysser
du av punkt A, fyller ut spørreskjemaet og returnerer det til oss i vedlagte kon-
volutt. Du vil senere få et brev med tid og sted for fremmøte sammen med et
nytt spørreskjema.
B Dersom du bare ønsker å delta i en innledende del av forskningsprosjektet uten
helseundersøkelse, krysser du av punkt B , fyller ut spørreskjemaet og returnerer
det til oss i vedlagte konvolutt. 
C Du kan unngå purring fra oss ved å krysse av punkt C og returnere spørre-
skjemaet til oss. Purring vil skje skriftlig.
Datatilsynet har gitt konsesjon for lagring av opplysninger fra undersøkelsen og
forskningsprosjektet er tilrådd av Regional komite for medisinsk forskningsetikk i
Nord- Norge.
For forskningen sin del vil det være av stor interesse at vi får inn så mange opplys-
ninger som mulig. Du deltar frivillig og kan, etter å ha sagt ja til deltakelse, senere
trekke deg uten å begrunne hvorfor og uten at det vil ha noen konsekvenser for
deg. Det samme gjelder dersom man i utgangspunktet ikke ønsker å delta.
Opplysninger du har gitt kan du be om å få slettet.
Resultatene vil bli publisert i massemedia, og det utformes en rapport fra helse- og
levekårsundersøkelsen når den er avsluttet.
De som fullfører hele helse- og levekårsundersøkelsen vil være med i trekningen av
3 reisegavekort til en verdi av á kr. 10 000,–. Vi regner med en deltakelse på ca.
15000 personer.
Med hilsen
Anne Kirsten Anti Eiliv Lund Per G. Lund-Larsen








Hvordan er helsen din nå? (Sett bare ett kryss)
 Dårlig  Ikke helt god  God  Svært god
1 2 3 4
Har du, eller har du hatt? Alder første
JA NEI gang
Astma  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
Kronisk bronkitt/emfysem/KOLS  . . . . . . . . . . .  
Diabetes (sukkersyke)  . . . . . . . . . . . . . . . . . . . . . . .  
Fibromyalgi/kronisk smertesyndrom  . . . . . .  
Psykiske plager som du har søkt hjelp for  
Hjerteinfarkt (sår på hjertet)  . . . . . . . . . . . . . . . .  
Angina pectoris (hjertekrampe)  . . . . . . . . . . . .  
Hjerneslag/hjerneblødning  . . . . . . . . . . . . . . . . .  
Multippel sklerose (MS)  . . . . . . . . . . . . . . . . . . . . .  
Ulcerøs kolitt  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
Får du smerter eller ubehag i brystet når du: JA NEI
Går i bakker, trapper eller fort på flatmark?  
Kan slike smerter opptre selv om du er i ro?  
2. MUSKEL OG SKJELETTPLAGER
Har du i løpet av det siste året vært plaget
med smerter og/eller stivhet i muskler og
ledd som har vart i minst 3 måneder JA NEI
sammenhengende?  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
Alder
Har du noen gang hatt: JA NEI siste gang
Brudd i håndledd/underarm? . . . . . . . . . . . . . . .  
Lårhalsbrudd?  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
3. MAGE OG TARM SYMPTOMER
Har du hatt sure oppstøt, halsbrann eller JA NEI
brystbrann nesten daglig i minst en uke?  
Har du noen gang hatt smerter eller verk
i magen som har vart i minst 2 uker?  
Hvis JA, hvor i magen sitter smertene? (Sett ett kryss)
 Øvre del  Nedre del  Hele magen
Er smertene eller «verken» jevnt over tilstede? (Sett ett kryss)
I perioder av ukers varighet  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
I perioder av måneders varighet  . . . . . . . . . . . . . . . . . . . . . . . . . . 
Bestandig  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Er du ofte plaget av oppblåsthet, rumling i JA NEI
magen eller rikelig luftavgang?   
3. MAGE OG TARM SYMPTOMER (fortsettelse)
Er avføringen din vanligvis: (Sett ett eller flere kryss)
 Normal  Løs  Hard og perlete
 Vekslende hard og løs  Illeluktende
JA NEI
Har du i perioder tre eller flere avføringer daglig?  
Har du hatt plager i mage/tarm etter inntak av melk?  
Er det andre i familien som har de samme magesymptomene?
 Mor  Far  Søsken  Barn  Ingen
4. ANDRE PLAGER
Under finner du en liste over ulike problemer. Har du opp-
levd noe av dette den siste uken (til og med i dag)?
(Sett ett kryss for hver plage)
Ikke Litt Ganske Veldig
plaget plaget mye mye
Plutselig frykt uten grunn . . . . . . . . .    
Føler deg redd eller  engstelig . . .    
Matthet eller svimmelhet . . . . . . . . .    
Føler deg anspent eller oppjaget    
Lett for å klandre deg selv . . . . . . . .    
Søvnproblemer . . . . . . . . . . . . . . . . . . . . .    
Nedtrykt, tungsindig . . . . . . . . . . . . . . .    
Følelse av å være unyttig, lite verd    
Følelse av at alt er et slit . . . . . . . . . .    
Følelse av håpløshet mht. framtida   
Tenkt på å gjøre slutt på livet ditt    
1 2 3 4
5. SYKDOM I FAMILIEN
VET
Har en eller flere av dine foreldre eller søsken JA NEI IKKE
hatt hjerteinfarkt eller angina pectoris?   
Kryss av for de slektningene som har eller har hatt noen av
sykdommene og angi deres alder for når de fikk sykdom-
mene. (Hvis flere søsken, før opp den som fikk det tidligst i livet)
Alder første 
Mor Far Søster Bror Barn Ingen gang
Hjerteinfarkt før 
60-års alder  . . . . .      
Hjerteinfarkt 
etter 60 års-alder      
Diabetes  . . . . . . . . .      
Hjerneslag  . . . . . . .      
Astma  . . . . . . . . . . . .      
Tykktarmskreft  . .      
Brystkreft  . . . . . . . .      
Eggstokkreft  . . . . . .      
Hvor mange søsken har du? Brødre Søstre
6. BRUK AV MEDISINER
Med medisiner mener vi her medisiner kjøpt på apotek.
Kosttilskudd og vitaminer regnes ikke med her.
Bruker du? Nå Før, men ikke nå Aldri brukt
Medisin mot høyt blodtrykk  . . .   
Kolesterolsenkende medisin  . . .   
Insulin  . . . . . . . . . . . . . . . . . . . . . . . . . . . . .   
Tabletter mot sukkersyke  . . . . . .   
Hvor ofte har du i løpet av de siste 4 ukene brukt følgende
medisiner? (Sett ett kryss pr. linje)
Ikke Sjeldnere
brukt enn Hver uke,
siste hver men ikke
4 uker uke daglig Daglig
Smertestillende uten resept    
Smertestillende på resept    
Sovemedisin  . . . . . . . . . . . . . . . . . . .    
Beroligende medikamenter    
Medisiner mot depresjon    
Annen medisin på resept    
1 2 3 4
For de medisinene du har krysset av for i de to punktene
ovenfor og som du har brukt i løpet av de siste 4 ukene:
Angi navnet og hvilken grunn det er til at du tar/har tatt disse
(sykdom eller symptom):(Kryss av for hvor lenge du har brukt medisinen)
Navn på medisinen: Grunn til bruk Inntil 1 år  






Dersom det ikke er nok plass her, kan du fortsette på eget ark som du legger
ved.
7. MAT OG DRIKKE
Hvor ofte spiser du vanligvis disse matvarene?
(Sett ett kryss pr. linje)
Sjelden/ 1-3 g. 1-3 g. 4-6 g. 1-2 g. 3 g. el.
aldri pr.mnd pr. uke pr. uke pr. dag mer pr.
dag
Frukt  . . . . . . . . . . . . . . . . .      
Bær  . . . . . . . . . . . . . . . . . .      
Ost (alle typer)  . . . . .      
Poteter . . . . . . . . . . . . . . .      
Kokte grønnsaker      
Rå grønnsaker/salat      
1 2 3 4 5 6
7. MAT OG DRIKKE (fortsettelse)
Hva slags fett bruker du oftest? (Sett ett kryss pr. linje)
Bruker Meieri- Hard Myk/lett Oljer Annet
ikke smør margarin margarin
På brødet . . . . . . . . .     
I matlagingen . . . .     
1 2 3 4 5 6
Bruker du følgende kosttilskudd:
Ja, daglig Iblant Nei
Tran, trankapsler?  . . . . . . . . . . . . . . . . . . . . . . . . .   
Fiskeoljekapsler (omega 3)?  . . . . . . . . . . . . .   
Vitamin- og/eller mineraltilskudd?  . . . . .   
Hvor mye drikker du vanligvis av følgende? (Sett ett kryss pr. linje)
Sjelden/ 1-6 1 2-3 4 glass
aldri glass glass glass el. mer
pr. uke pr. dag pr. dag pr. dag
Helmelk, kefir, yoghurt  . .     
Lettmelk, cultura,
lett yoghurt  . . . . . . . . . . . . . . . .     
Skummet melk (sur, søt)     
Ekstra lettmelk  . . . . . . . . . . . .     
Fruktjuice  . . . . . . . . . . . . . . . . . .     
Vann  . . . . . . . . . . . . . . . . . . . . . . . .     
Brus/Cola med sukker  . . .     
Brus/Cola uten sukker  . . .     
1 2 3 4 5
Hvor mange kopper kaffe og te drikker du daglig?
(Sett 0 for de typene du ikke drikker daglig) Antall kopper
Filterkaffe . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Kokekaffe/trykkanne  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Annen kaffe . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Te . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Omtrent hvor ofte har du i løpet av det siste året drukket
alkohol? (Lettøl og alkoholfritt øl regnes ikke med)
Har aldri Har ikke Noen få Omtrent 1
drukket drukket ganger gang i
alkohol siste år siste år måneden
 1  2  3  4
2-3 ganger Ca. 1 gang 2-3 ganger 4-7 ganger
pr. måned i uka i uka i uka
 5  6  7  8
Til dem som har drukket siste år:
Når du har drukket, hvor mange glass
eller drinker har du vanligvis drukket?     Antall
Omtrent hvor mange ganger det siste
året har du drukket så mye som minst     Antall
5 glass eller drinker i løpet av ett døgn?  ganger
Når du drikker, drikker du da vanligvis: (Sett ett eller flere kryss)
 Øl  Vin  Brennevin
Hvor lenge?
8. RØYKING OG BRUK AV SNUS
Hvor lenge er du vanligvis
daglig i et røykfylt rom? Antall hele timer
Røykte noen av de voksne hjemme da du JA NEI
vokste opp?  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
Bor du, eller har du bodd, sammen med noen JA NEI
dagligrøykere etter at du fylte 20 år? . . . . . . . . . . . . . . . .  
Ja, nå Ja, før Aldri
Har du røykt/røyker du daglig?   
Hvis du røyker daglig nå, røyker du: JA NEI
Sigaretter?  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
Sigarer/sigarillos/pipe?  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
Rulletobakk/rullings?  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
Hvis du har røykt daglig tidligere, hvor
lenge er det siden du sluttet? Antall år
Hvis du røyker daglig nå, eller har røykt tidligere:
Hvor mange sigaretter røyker/røykte
du vanligvis daglig? Antall sigaretter
Hvor gammel var du da du begynte å
røyke daglig? Alder i år
Hvor mange år til sammen har du
røykt daglig? Antall år
Ja, nå Ja, før Aldri
Har du brukt/bruker du snus daglig?    
Hvis du bruker/har brukt snus, hvor
mange år til sammen har du brukt snus? Antall år
9. MOSJON OG FYSISK AKTIVITET
Hvordan har din fysiske aktivitet i fritiden vært det siste
året? (Tenk deg et ukentlig gjennomsnitt for året. Arbeidsvei
regnes som fritid. Besvar begge spørsmålene)
T i m e r  p r .  u k e :
Lett aktivitet Ingen Under 1 1-2 3 og mer
(Ikke svett/andpusten)  . . . . .   
Hard fysisk aktivitet
(Svett/andpusten)  . . . . . . . . .   
1 2 3 4
Angi bevegelse og kroppslig anstrengelse i din fritid. Hvis
aktiviteten varierer meget f. eks. mellom sommer og vinter,
så ta et gjennomsnitt. Spørsmålet gjelder bare det siste året.
(Sett kryss i den ruta som passer best)
Leser, ser på fjernsyn eller annen
stillesittende beskjeftigelse?  . . . . . . . . . . . . . . . . . . . . . . . . . . .  1
Spaserer, sykler eller beveger deg på annen 
måte minst 4 timer i uka?  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2
(Regn også med gang eller sykling
til arbeidsstedet, søndagsturer m.m.)
Driver mosjonsidrett, tyngre hagearbeid e.l.?  . . . . . .  3
(Merk at aktiviteten skal vare minst 4 timer i uka)
Trener hardt eller driver konkurranseidrett
regelmessig og flere ganger i uka?  . . . . . . . . . . . . . . . . . . .  4
10. UTDANNING OG ARBEID
Hvor mange års skolegang har du gjennomført?
(Ta med alle år du har gått på skole eller studert) Antall år
Hvordan trives du i din jobb?
1  Svært godt 2  Godt 3  Dårlig 4  Veldig dårlig
Mener du at du står i fare for å miste ditt
nåværende arbeid eller inntekt de JA NEI
nærmeste 2 årene?  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
Mottar du noen av følgende ytelser? JA NEI
Sykepenger  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
Attføring  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
Sosialhjelp/-stønad  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
Overgangsstønad for enslige forsørgere  . . . . . . . . . . . . . .  
11. RESTEN AV SKJEMAET SKAL BARE BESVARES AV KVINNER
Hvor gammel var du da du fikk
menstruasjon aller første gang? Alder i år
Hvis du ikke lenger får menstruasjon,
hvor gammel var du da den sluttet? Alder i år
Er du gravid nå? Over fruktbar
Ja Nei Usikker alder
 1  2  3  4
Hvor mange barn har du født? Antall barn
Hvis du har født barn, fyll ut hvert barns fødselsår, og hvor
mange måneder du ammet etter fødselen. 
(Hvis du ikke ammet, skriv 0) Ammet
Barn: Fødselsår: antall mnd.:
1. barn . . . . . . . . . . . . . . . . . . . . .
2. barn . . . . . . . . . . . . . . . . . . . . .
3. barn . . . . . . . . . . . . . . . . . . . . .
4. barn . . . . . . . . . . . . . . . . . . . . .
5. barn . . . . . . . . . . . . . . . . . . . . .
(Hvis flere barn, bruk ekstra ark)
Bruker du, eller har du brukt? (Sett ett kryss for hver linje)
Nå Før, men Aldri
ikke nå
P-pille/minipille/p-sprøyte . . . . . . . . . . . . . . .   
Hormonspiral (ikke vanlig spiral)  . . . . . .   
Østrogen (tabletter eller plaster) . . . . . . . .   
Østrogen (krem eller stikkpiller) . . . . . . . .   
Hvis du bruker/har brukt reseptpliktig østrogen:
Hvor lenge har du brukt dette? Antall år
Hvis du bruker p-pille, minipille, p-sprøyte, hormonspiral



































Hvor mange ganger de siste 12 måneder har du selv brukt:
(sett ett kryss for hver linje)
Ingen 1-3 ganger 4 eller flere
Kommunelege/fastlege   
Spesialist   
Legevakt   
Sykehus innleggelse   
Hjemmesykepleie   
Kommunal hjemmehjelp   
Fysioterapeut   
Kiropraktor   
Tannlege   
Alternativ behandler   
Hvor mange leger har du selv vært hos de siste 12 måneder?
(angi antall)
Har du fått tildelt navngitt fastlege?  Ja  Nei
Når du er til undersøkelse, hvilket språk kommuniserer du
og legen på? (sett ett eller flere kryss)
 Norsk  Samisk  Bruker tolk  Annet språk
Tror du det skjer noen gang at du og legen misforstår
hverandre p.g.a. språklige problemer?
 Aldri  Sjelden  Av og til  Ofte  Usikker
Dersom det er behov for tolk, synes du at legen er flink nok
til å be om det?
 Ja, alltid  Ja, som regel  Nei, ikke alltid
 Nei, aldri  Jeg liker ikke å bruke tolk
Hvor fornøyd eller misfornøyd er du med følgende sider
ved den kommunale legetjenesten i din bostedskommune?
(sett ett kryss per linje)
Meget Fornøyd Misfornøyd Meget Vet
fornøyd misfornøyd ikke
Avstand til legen     
Legens tilgjengelighet
på telefon      
Ventetid på legetime     
Tid inne hos legen     
Mulighetene for å få
fortalt om dine plager     
Legens forståelse av




behandlingsopplegg     
BRUK AV HELSETJENESTER (fortsettelse)
Meget Fornøyd Misfornøyd Meget Vet
fornøyd misfornøyd ikke
Legens språkbeherskelse
(samisk eller norsk)     
Totalt sett, hvor fornøyd
eller misfornøyd er du
med den kommunale
legetjenesten?     
Hvor lenge er det siden du var hos lege sist? (angi i hele tall)
(år)                           (måneder)
Dersom du noen gang har benyttet alternative behandlere,
hvilke har du brukt? (sett ett eller flere kryss)
 Helbreder (guvllár, leser, blåser, håndspålegger)
 Healer
 Akupunktør
 Soneterapeut, homeopat, kinesiolog osv.
Dersom du har benyttet en alternativ behandler, hvor lenge
er det siden sist? (angi i hele tall)
(år)                          (måneder)
Tenk deg at du i dag skulle få behov for hjelp/bistand fra
den kommunale helse- og sosialtjenesten (hjemmesykepleie,
hjemmehjelp, sosiale tjenester, fysioterapi o.s.v.)
Vet du hvor du skal henvende deg?
 Ja  Nei  Usikker
Er du trygg på at du får hjelp hvis du trenger det?
 Ja  Nei  Usikker
Dersom du i dag får hjelp fra den kommunale helse- og
sosial tjenesten, er du fornøyd med tilbudet? 
 Ja  Nei  Usikker
SKADER/ULYKKER
Har du vært utsatt for noen ulykker som medførte behand-
ling hos lege og/eller sykehusinnleggelse?
Lege  Ja  Nei antall ganger
Sykehus innleggelse  Ja  Nei antall ganger
SKADER/ULYKKER (fortsettelse)
Hvis ja, hva slags ulykke(r) er du blitt behandlet for?
(sett ett eller flere kryss pr. linje)
Arbeid Hjem Fritid Ingen
Bil . . . . . . . . . . . . . . . . . . .    
Motorsykkel . . . . . .    
Snøscooter. . . . . . . . .    
Firehjulssykkel . . . .    
Traktor . . . . . . . . . . . . . .    
Fallulykke. . . . . . . . . .    
Kuttskade . . . . . . . . . .    
Annet . . . . . . . . . . . . . . .    
Har ulykken(e) ført til nedsatt arbeidsevne?
 Helt  Delvis  Ikke i det hele tatt
FAMILIE OG SPRÅKBAKGRUNN
I Nord-Norge bor det folk med ulik etnisk bakgrunn. Det vil
si at de snakker ulike språk og har forskjellige kulturer.
Eksempler på etnisk bakgrunn, eller etnisk gruppe er norsk,
samisk og kvensk. 
Hvilket hjemmespråk har/hadde du, dine foreldre og beste-
foreldre? (sett ett eller flere kryss)
Norsk Samisk Kvensk Annet, beskriv
Morfar:     . . . . . . . . . . . . . . . . . . . . . 
Mormor:     . . . . . . . . . . . . . . . . . . . . . 
Farfar:     . . . . . . . . . . . . . . . . . . . . . 
Farmor:     . . . . . . . . . . . . . . . . . . . . . 
Far:     . . . . . . . . . . . . . . . . . . . . . 
Mor:     . . . . . . . . . . . . . . . . . . . . . 
Jeg selv:     . . . . . . . . . . . . . . . . . . . . . 
Hva er din, din fars og din mors etniske bakgrunn?
(sett ett eller flere kryss)
Norsk Samisk Kvensk Annet, beskriv
Min etniske bakgrunn er:     . . . . . . . . . . .
Fars etniske bakgrunn er:     . . . . . . . . . . .
Mors etniske bakgrunn er:     . . . . . . . . . . .
Hva regner du deg selv som? (sett ett eller flere kryss)
Norsk Samisk Kvensk Annet, beskriv
     . . . . . . . . . . .
ARBEIDSLIV/ØKONOMI
Hvilken type arbeid/livsopphold har du? (sett ett eller flere kryss)
 Fastlønnet, heltid  Fastlønnet, deltid
 Sesongarbeid  Selvstendig næringsdrivende
 Arbeidsledig  Hjemmeværende
 Alderstrygd  Uføretrygd
 Annet (beskriv) ............................................................................................................
ARBEIDSLIV/ØKONOMI (fortsettelse)
Kunne du tenke deg å flytte fra din bostedskommune der-
som du fikk tilbud om arbeid et annet sted?
 Ja  Nei  Deler av året  Usikker
Dersom du er arbeidsledig, angi hvor lenge du har vært
arbeidssøker: (angi i hele tall)
(år)                            (måneder)
Dersom du er selvstendig næringsdrivende, hvilken type
næring jobber du i? (sett ett eller flere kryss)
 Reindrift  Fiske  Jordbruk  Skogbruk
 Forretningsvirksomhet  Annet (spesifiser)  . . . . . . . . . . . . .
Hvor mange personer bor det i din husstand?
(antall personer)
Hvor stor er familiens/husstandens bruttoinntekt per år?
 Under kr. 150000  Kr. 150 000–300 000
 Kr. 301 000–450 000  Kr. 451 000–600 000
 Kr. 601 000–750 000  Over kr. 750 000
Hvor ofte spiller du på ulike pengespill slik som lotto, tip-
ping, spilleautomater og lignende?
 Aldri/sjelden  1-3 ganger i mnd.
 1 gang i uka  2-6 ganger i uka  Hver dag
Hvor mye spiller du for ukentlig i gjennomsnitt?
 Under kr. 100 i uka  Kr. 100-500 i uka
 Kr. 501–1000 i uka  Over kr. 1000 i uka
MOBBING
Med mobbing mener vi når en eller flere personer gjentatte
ganger sier eller gjør vonde ting mot deg, og du har vanske-
ligheter med å forsvare deg.
Har du vært utsatt for mobbing?
 Ja, de siste 12 mnd.  Ja, før  Nei
Dersom du har vært utsatt for mobbing, hvilken type mob-
bing er du blitt utsatt for? (sett ett eller flere kryss)
 Baksnakking  Ignorering
 Diskriminerende bemerkninger  Annet
Kan du angi hvor dette foregår/foregikk?
(sett ett eller flere kryss)
 På skolen  På skoleinternat  I yrkeslivet






The SAMINOR 2 Clinical Survey 
 
Original Norwegian versions of: 
         Pamphlet 
Information brochure 
Invitation letter (Illustrated by information letter to Karasjok municipality) 
Informed written consent form 
Questionnaire (for 40–69 years participants) 




Vi kommer nå til din kommune
Du vil i løpet av noen uker motta en forespørsel i 
posten fra Universitetet i Tromsø om å delta i en 
helseundersøkelse. Resultatene vil kunne bidra til å 
fremme folkehelse og forbedre velferdstilbud i nord.
HVorfor spør Vi deg?
Alle mellom 40 – 79 år i din kommune vil bli invitert. 
Hver deltaker er like viktig, enten du er ung eller gam-
mel, kvinne eller mann, frisk eller syk. Godt oppmøte 






Vi ber deg også om å fylle ut et spørreskjema.
tilbakemelding på resultater
Dersom du ønsker det, vil du ved undersøkelsen få 
dine egne resultater på høyde, vekt, liv- og hoftemål, 
blodtrykk, puls, blodprosent og langtidsblodsukker.
din sikkerHet 
Det er frivillig å delta. 
Din sikkerhet er høyt ivaretatt. All behandling av 
helseopplysninger eller prøvemateriale skjer i tråd 
med helseforskningsloven. Alle opplysninger og 
prøver anonymiseres og blir da behandlet uten navn 
og fødselsnummer eller andre direkte gjenkjennbare 
opplysninger.
Undersøkelsen er godkjent av Datatilsynet og REK 
Nord – Regional komite for medisinsk og helsefaglig 
forskningsetikk.
Foto: Bjørn-Kåre Iversen, helsefak. uit.no
Foto: Bjørn Erik Rygg Lunde/ Nordlandssykehuset
Helse- og livsstils- 
undersøkelse
institutt for Helse- og omsorgsfag
universitetet i tromsø uit
det helsevitenskapelige fakultet
Vi kommer nå til din 
kommune
Du vi i løpet av noen uker motta et 
brev om sted og tid for undersøkelsen. 
Ved å delta, bidrar du til spennende og 
samfunnsnyttig forskning på helse og 
livsstil i nord. 
dersom du Har spørsmål 
ta gjerne kontakt med oss på telefon 
eller via e-post.




















































Foto: Bård Løken/NordNorsk Reiseliv
Illustrasjonsfoto: www.colorbox.com
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Alle som deltar vil være med i trekning av to  
reisegavekort verdt kr 10 000,- hver. I tillegg vil det 
trekkes to ekstra reisegavekort i den kommunen som 
har best deltagelse. Ut over dette gis det ingen  
økonomisk kompensasjon for deltakelse i studien.
Foto: Bjørn-Kåre Iversen, helsefak. uit.no
Hva skjer med prøvene og  
informasjonen om deg? 
Prøvene tatt av deg og informasjonen som registreres 
om deg skal kun brukes slik som beskrevet i hensikten 
med studien. Videre behandling av helseopplysninger 
eller prøvemateriale skjer i tråd med helseforsknings-
loven og eventuell annen aktuell lovgivning. Alle 
opplysninger og prøver vil bli behandlet uten navn og 
fødselsnummer eller andre direkte gjenkjennende opp-
lysninger. En kode knytter deg til dine opplysninger og 
prøver gjennom en navneliste. Det betyr at opp- 
lysningene er avidentifisert. Det er kun autorisert  
personell knyttet til prosjektet som har adgang til 
navnelisten og som kan finne tilbake til deg. Det vil 
heller ikke være mulig å identifisere deg i resultatene av 
studien når disse publiseres. Du kan seinere bli  
kontaktet med forespørsel om du vil svare på tilleggs-
spørreskjema.
Opplysninger som registreres om deg er basert på  
spørreskjemaopplysninger, mål fra helseundersøkelsen 
og blodprøveanalyser. Etter godkjenning fra Data- 
tilsynet og/eller REK kan opplysningene dine settes 
sammen med opplysninger om deg i andre registre for 
forskningsformål. Dette kan være registre om trygd, 
sykdom, inntekt, utdanning, yrke og opplysninger fra 
andre helseundersøkelser som du har deltatt i. Aktuelle 
registre er Kreftregisteret, Dødsårsaksregisteret, Folke-
registeret, Reseptregisteret, Medisinsk fødselsregister, 
Hjerte- og karregisteret og andre nasjonale registre over 
sykdommer som det forskes på i denne undersøkelsen 
samt registre i Statistisk sentralbyrå og folketellinger. 
I alle disse tilfellene blir navnet og personnummeret 
fjernet. Forsikringsselskaper eller andre kommersielle 
institusjoner vil ikke få tilgang til dataene. 
Prosjektslutt er satt til 31. desember 2067. Etter dette 
anonymiseres alle dataene.
BioBank 
Blodprøvene vil bli lagret i en såkalt forskningsbiobank 
ved Universitetet i Tromsø eller eventuelt ved et annet 
nasjonalt lager for biobank med høyeste grad av  
sikkerhet i forhold til prøvens kvalitet og personvern 
som er godkjent av aktuelle instanser. Hvis du sier ja til 
å delta i studien, gir du også samtykke til at blod- 
prøvene inngår i denne biobanken. Universitetet i 
Tromsø er ansvarshavende for forskningsbiobanken. 
BeHandlingsansvarlig
Universitetet i Tromsø ved administrerende direktør er 
databehandlingsansvarlig.
rett til innsyn og sletting av opplys-
ninger og prøver 
Hvis du sier ja til å delta i studien, har du rett til å få 
innsyn i hvilke opplysninger som er registrert om deg. 
Du har videre rett til å få korrigert eventuelle feil i de 
opplysningene vi har registrert. Dersom du trekker deg 
fra studien, kan du kreve å få slettet innsamlede prøver 
og opplysninger, med mindre opplysningene allerede er 
inngått i analyser eller brukt i vitenskapelige  
publikasjoner. 
kompensasjon
Det gis ingen økonomisk kompensasjon for deltakelse i 
studien bortsett fra at alle som deltar vil være med i  
trekning av to reisegavekort hver verdt kr 10 000,-.  
I tillegg vil det trekkes to ekstra reisegavekort i den 
kommunen som har best deltagelse.
økonomi 
Studien og biobanken er finansiert gjennom  
forskningsmidler fra det Regionale forskningsfond 
Nord-Norge, de tre nordligste fylkeskommunene, Helse 
Nord, Sametinget, Universitetet i Tromsø og Helse  
og omsorgsdepartementet. Ingen av disse instansene 
har interessekonflikter i undersøkelsen.
forsikring
Deltakerne er dekket gjennom pasientskade- 
erstatningsloven. 
Bakgrunn og Hensikt
Dette er et spørsmål til deg om å delta i et forsknings-
prosjekt for å få mer kunnskap om helse, sykdom og 
levekår i områder med samisk og norsk bosetting. Du 
som deltar i denne undersøkelsen får sjekket om du har 
bestemte såkalte livsstilssykdommer eller om det er fare 
for at du kan få dem. 
Du er invitert til å være med i denne studien fordi du er 
i alderen 40-79 år og tilhører en av de utvalgte kommu-
ner. Studien utføres av Senter for samisk helse- 
forskning, Institutt for samfunnsmedisin ved  
Universitetet i Tromsø.
Hva inneBærer studien?
Du inviteres til å svare på vedlagte spørreskjema og ta 
det med når du møter opp på anvist forskningsstasjon 
i din kommune. Her vil det gjøres målinger av blod-
trykk, puls, høyde, vekt og liv-hoftevidde, og det blir 
også tatt blodprøve. 
Blodprøvene kan senere bli analysert for nærings- 
stoffer, miljøgifter, fettstoffer og markører som kan 
knyttes til livsstilssykdommer eller tilstander som for 
eksempel diabetes (sukkersyke), hjerte-karsykdommer 
og søvnforstyrrelser. Genetiske analyser av blodet for å 
finne mulige årsaker til nevnte livsstilssykdommer/ 
tilstander kan også bli aktuelt. 
All bruk av blodprøvene krever godkjenning av  
Regional komité for medisinsk og helsefaglig 
forskningsetikk – REK nord. 
Vedlagt følger informasjon om tid og sted for under-
søkelsen. Hvis den foreslåtte tiden ikke passer, kan du 
møte opp uten å melde fra på forhånd.
mulige fordeler og ulemper
Det forventes ingen risiko forbundet med deltagelse i 
denne undersøkelsen. Blodprøven blir tatt ved stikk i 
blodåre i underarmen. Selve undersøkelsen vil ta om 
lag en halv time. Du vil på stedet få tilbud om resultater 
på egne målinger som blodtrykk, puls, høyde, vekt og 
liv-hoftevidde, blodprosent og HbA1c (gjennomsnittlig 
blodsukker de siste 6-8 ukene). Du kan reservere deg 
mot å få vite resultatene av prøvene dine. Men hvis et av 
disse prøveresultatene er slik at det er nødvendig med 
rask legebehandling, vil du uansett umiddelbart få  
tilbakemelding. Deltagelse i denne studien erstatter 
ingen legeundersøkelse. Dersom du har mistanke om 
noe galt med din helse, må du derfor i tillegg oppsøke 
din egen fastlege.
Det helsevitenskapelige fakultet
UNIVERSITETET I TROMSØ UIT
DET HELSEVITENSKAPELIGE FAKULTET
uit.no/helsefak
S   minor 2
Helse- og levekårsundersøkelse
S   minor 2
Helse- og levekårsundersøkelse
S   minor 2
Helse- og levekårsundersøkelse
S   minor 2
Helse- og levekårsundersøkelse
S   minor 2
Helse- og levekårsundersøkelse
S   minor 2













































Foto: Bård Løken/NordNorsk Reiseliv
FORESpØRSEl OM  
dElTakElSE I  
hElSE- Og lIVSSTIlS-
UNdERSØkElSE
informasjon om utfallet av 
studien
Resultater av undersøkelsen vil publiseres i  
internasjonale og nasjonale vitenskapelige tidsskrifter i 
tillegg til ulike populærvitenskapelige  
kanaler og media.
frivillig deltakelse
Det er frivillig å delta i studien. Dersom du  
ønsker å delta, møter du opp til angitt sted og  
tidspunkt. Her vil du bli bedt om å signere et samtykke 
på deltakelse. Du kan når som helst og uten å oppgi 
noen grunn trekke ditt samtykke til å delta i studien. 
Dersom du senere ønsker å trekke deg eller har 
spørsmål til studien, kan du kontakte oss på vår  
prosjektelefon: 404 90 467 eller på  
e-post: saminor@ism.uit.no











Kosthold – diabetes – hjerte-karsykdommer – miljøgifter – tannhelse – søvn
Senter for samisk helseforskning / Sámi dearvvašvuođadutkama guovddáš
Det helsevitenskapelige fakultet, Institutt for samfunnsmedisin, 
Universitetet i Tromsø, NO-9037 Tromsø
http://site.uit.no/helseoglivsstil/ • http://saminor.uit.no • E-post: saminor@ism.uit.no
Sentralbord: 77 64 40 00 • Faks: 77 64 48 31• Mobil: 404 90 467 
Forespørsel om deltakelse i forskingsprosjekt
Vi spør deg om å delta i en helse- og livsstilsundersøkelse som Universitetet i Tromsø 
nå gjennomfører. Hele befolkningen i alderen 40-79 år i utvalgte distriktskommuner i 
Nord-Norge får tilbud om undersøkelsen. Karasjok kommune er først ut i Finnmark.
Vi inviterer deg til å møte opp på denne undersøkelsen som vil finne sted i tidsrommet 
28. januar til 21. februar 2013 ved:
Sentrumsbygget, Fidnodatgeaidnu 39 i Karasjok.
 
For å avvikle undersøkelsen raskest mulig, setter vi opp et visst antall personer i 
timen. 
Du har fått tildelt frammøtetid:
Dato:
Tid:          
         
Om du ikke kan møte opp til avtalt time, er du velkommen til å møte opp når som helst 
i åpningstiden for drop-in som skissert under. Merk at åpningsdagen åpner vi klokken 
11:00, og vi har lunsj i tidsrommet 12:00 -12:30.
 Mandag Tirsdag Onsdag Torsdag Fredag Lørdag
Uke 5 10:00 - 16:30 10:00 - 18:00 10:00 - 16:30 10:00 - 16:30 10:00 - 16:30 STENGT
Uke 6 10:00 - 16:30 10:00 - 18:00 STENGT 10:00 - 16:30 10:00 - 16:30 10:00 - 14:00
Uke 7 10:00 - 16:30 10:00 - 18:00 10:00 - 16:30 10:00 - 16:30 10:00 - 16:30 10:00 - 14:00
Uke 8 10:00 - 16:30 10:00 - 18:00 10:00 - 16:30 10:00 - 16:30 STENGT STENGT
Helse og livsstil 
Kosthold – diabetes – hjerte-karsykdommer – miljøgifter – tannhelse – søvn
Senter for samisk helseforskning / Sámi dearvvašvuođadutkama guovddáš
Det helsevitenskapelige fakultet, Institutt for samfunnsmedisin, 
Universitetet i Tromsø, NO-9037 Tromsø
http://site.uit.no/helseoglivsstil/ • http://saminor.uit.no • E-post: saminor@ism.uit.no
Sentralbord: 77 64 40 00 • Faks: 77 64 48 31• Mobil: 404 90 467 
Hva undersøkes? 
På stedet undersøker vi ditt blodtrykk, din puls, høyde, vekt og liv- hoftevidde, samt at 
vi tar en blodprøve av deg.
Ta med ditt utfylte spørreskjema til undersøkelsen
Vi ber deg om å svare på vedlagte spørreskjema og ta dette med for levering på 
undersøkelsesdagen. Her kan du også få hjelp til utfylling av skjemaet om du trenger 
det. Du kan la være å svare på enkelte spørsmål. Spørreskjemaet omhandler i 
hovedsak spørsmål vedrørende hjerte-karsykdommer, diabetes og kosthold. For å 
kunne beregne næringsinntak (kalorier, næringsstoffer o.l.) er det nødvendig med en 
grundig kartlegging av hva du normalt spiser.
Forberedelser til undersøkelsen
Ha gjerne på et kortermet plagg innerst som ikke strammer da det letter 
blodtrykksmålingen. Vekt og liv-hoftevidde måles også med lett påkledning og vekt 
uten sko. Ingen andre forberedelser som fasting o.l. er nødvendig. 
Det er frivillig å delta. For mer informasjon om undersøkelsen, vennligst se 
vedlagte informasjonsfolder. 
Har du spørsmål om undersøkelsen, kan du ringe Institutt for samfunnsmedisin ved 












1.  I hvilket år er du født? ..........................................................................
2. Er du? ............................................................................................................................
Kvinne Mann




4. Hvor mange personer bor det i din husstand? ...........
Antall år
5. Hvor mange års skolegang har du gjennom ført? 
(Ta med alle år du har gått på skole eller studert) ...............................................
6. Hvor stor er familiens/husstandens bruttoinntekt pr. år?
Under kr 150 000 Kr 150 000–300 000
Kr 301 000–450 000 Kr 451 000–600 000
Kr 601 000–750 000 Kr 751 000–900 000
Over kr 900 000
Hjerte -karsykdommer
7. Bruker du medisin mot høyt 
blodtrykk? ....................................................................
Ja, nå Før, men ikke nå Aldri brukt
8. Hvis du bruker eller tidligere har brukt 
blodtrykksmedisin, omtrent hvor gammel var 
du første gang du begynte med slik medisin?
Alder
9. Har du hatt hjerteinfarkt? 
Nei, aldri 1 gang 2 ganger 3 eller flere ganger
10. Hvis ja, hva var din alder første gang du fikk 
hjerteinfarkt? .............................................................................................................
Alder
11. Har du angina pectoris (hjertekrampe)?  .......... Ja Nei
12. Hvis ja, hva var din alder første gang du fikk 
angina pectoris? ....................................................................................................
Alder








7 eller flere 
ganger pr. uke
14. Har du blitt hjerteoperert (bypass)?  ...................
Ja Nei
15. Har du blitt blokket/fått innsatt stent? ..........
Ja Nei
16. Har legen sagt at du har hjerteflimmer? .....
Ja Nei
Fysisk aktivitet
17. Vi ber deg angi din fysiske aktivitet etter en skala fra svært 
lite til svært mye da du var 14 år, 30 år og i dag. Skalaen 
nedenfor går fra 1-10. Med fysisk aktivitet mener vi både arbeid i 
hjemmet og i yrkeslivet, samt trening og annen fysisk  
aktivitet som turgåing o.l. Sett kryss under det tallet som  
best angir ditt nivå av fysisk aktivitet.
Svært lite Svært mye





18. Har du noen gang fått påvist diabetes 
(for høyt blodsukker)?  ............................................................................ Ja Nei
Dersom nei, gå videre til spørsmål 28 om spisevaner  
19. Dersom ja, hvilken type diabetes har du fått påvist?  
(Sett ett eller flere kryss)
Svangerskapsdiabetes  ..............................................................................
Diabetes type I  ......................................................................................................
Diabetes type II  ....................................................................................................
20. Hvordan ble din diabetes oppdaget? 
Jeg søkte lege pga. symptomer .................................................. Ja Nei
Ble oppdaget uten at jeg hadde symptomer 
(legeattest, bedriftskontroll, svangerskapskontroll, 
undersøkelse for annen sykdom e.l.) .......................................................... Ja Nei
Alder
21. Hvor gammel var du da din diabetes ble 
oppdaget? ....................................................................................................................................................
INSULIN
22. Bruker du insulin mot  
din diabetes? ...........................................................
Ja, nå Før, men ikke nå Aldri brukt
Helse - og 
livsstils-
undersøkelse
Vi ber deg fylle ut spørreskjema så nøye som mulig og levere det ved oppmøte til den 
innkalte helseundersøkelsen. Skjema skal leses optisk. Vennligst bruk blå eller sort 
penn. Bruk blokkbokstaver. Du kan ikke bruke komma, forhøy for eksempel 0,5 til 1.
Dersom du bruker eller har brukt insulin:
Alder
23. Hvor gammel var du da du begynte med 
insulin? ................................................................................................................................
24. Hvor mange ganger pr. dag tar du/tok du 
vanligvis insulin? ............................................................................................... ganger
25. Hvor mange enheter insulin tar du/tok du 
vanligvis til sammen pr. dag? ...................................................... enheter(E)
TABLETTER
26. Bruker du tabletter mot  
din diabetes? ...........................................................
Ja, nå Før, men ikke nå Aldri brukt
Dersom du bruker eller har brukt tabletter:
Alder
27. Hvor gammel var du da du begynte med 
tabletter mot diabetes? .........................................................................
Spisevaner
Sett et kryss i ruten under det tallet som beskriver spisevanene 
dine slik du synes de har vært de siste 4 ukene:
28. Hvor fornøyd har du vært med spisevanene dine?  
(Sett ett kryss)
1 2 3 4 5 6 7
Svært misfornøyd Svært fornøyd
29. Har du trøstespist eller spist ekstra på grunn av at du har 
vært nedstemt eller følt deg utilfreds? (Sett ett kryss)
1 2 3 4 5 6 7
Aldri Hver dag
30. Har du hatt skyldfølelse i forbindelse med spising? (Sett ett kryss)
1 2 3 4 5 6 7
Aldri Hver dag
31. Har du følt at det er nødvendig for deg å følge strenge 
dietter eller andre matritualer for å holde kontroll med hvor 
mye du spiser? (Sett ett kryss)
1 2 3 4 5 6 7
Aldri Hver dag
32. Har du følt at du er for tykk? (Sett ett kryss)
1 2 3 4 5 6 7
Aldri Hver dag
Røykevaner
33. Har du noen gang røykt daglig? ................................. Ja Nei
Dersom du aldri har røykt daglig, kan du gå videre til spørsmål 
38.
34. Røyker du daglig nå? ...................................................................... Ja Nei
Alder
35. Hvis du har sluttet å røyke daglig, hvor gammel 
var du da du sluttet? ...........................................................................................................
År
36. Hvor mange år til sammen har du røykt daglig?
37. Hvor mange sigaretter/rulletobakk har du 
i gjennomsnitt røykt daglig i de årene du har 
røykt daglig? ............................................................................................................................
38. Bor du sammen med noen som røyker? ....... Ja Nei
Smerter
39. Har du smerter nå som har vart i  
tre måneder eller lengre? .................................................................. Ja Nei
40. Hvis ja, vennligst angi hvor sterke smerter du har hatt den 





0 1 2 3 4 5 6 7 8 9 10
41. Angi hvor smertene er mest plagsomme: (Sett ett kryss)
Nakke Korsrygg Annet
Kosthold
Vi er interessert i å få kjennskap til hvordan kostholdet ditt 
er vanligvis. Kryss av for hvert spørsmål om hvor ofte (antall 
ganger) du i gjennomsnitt siste året har brukt den  aktuelle 
matvaren, og hvor mye du pleier å spise/drikke hver gang.
DRIkkE
42. Hvor mange glass melk drikker du vanligvis av hver type? 













Helmelk (søt, sur) ..........................................
Lettmelk (søt, sur) ........................................
Ekstra lettmelk ..............................................
Skummet (søt, sur) .....................................
43. Hvor mange kopper kaffe/te drikker du vanligvis av hver 






















44. Bruker du følgende i kaffe?
Sukker (ikke kunstig søtstoff) ............................................................................. Ja Nei
Melk eller fløte ........................................................................................................... Ja Nei
45. Bruker du følgende i te?
Sukker (ikke kunstig søtstoff) .............................................................................. Ja Nei
Melk eller fløte ............................................................................................................ Ja Nei
46. Hvor mange glass vann drikker du vanligvis?  

















47. Hvor mange glass juice, saft og brus  















Saft/brus med sukker ........
Saft/brus, sukkerfri ................
YoghURT/koRNBLANDINg
48. Hvor ofte spiser du yoghurt (1 beger)? (Sett ett kryss)
Aldri/sjelden 1–3 pr. uke
4–6 pr. uke 1 + pr. dag
49. Hvor ofte spiser du kornblanding, havregryn eller müsli? 
(Sett ett kryss)
Aldri/sjelden 1–3 pr. uke
4–6 pr. uke 1 + pr. dag
BRøDmAT
50. Hvor mange skiver brød/rundstykker og knekkebrød/
skonrokker spiser du vanligvis? (½ rundstykke = 1 brødskive)  

















Nedenfor er det spørsmål om bruk av ulike påleggs typer. 
Vi spør om hvor mange brødskiver/knekkebrød med det 
aktuelle pålegget du pleier å spise. Dersom du også bruker 
matvarene i andre sammenhenger enn til brød (f.eks. til vafler, 
frokostblandinger, grøt), ber vi om at du tar med dette når du 
besvarer spørsmålene.
51. På hvor mange brødskiver/knekkebrød bruker du?  













Syltetøy..................................................... c c c c c c
Brunost (helfet) ................................. c c c c c c
Brunost (halvfet, mager) .......... c c c c c c
Hvitost (helfet) ..................................... c c c c c c
Hvitost (halvfet, mager)............. c c c c c c
Rekesalat, italiensk o.l. ..... c c c c c c
Leverpostei .............................................. c c c c c c
Magert kjøttpålegg  













Fett kjøttpålegg  
(salami, fenalår o.l.) ................................ c c c c c c
52. På hvor mange brødskiver/knekkebrød pr. uke har du i 













Makrell i tomat, røkt 
makrell ......................................................... c c c c c c
Kaviar ............................................................ c c c c c c
Sild/ansjos ............................................... c c c c c c
Laks (gravet/røkt) ............................... c c c c c c
Annet fiskepålegg ..................... c c c c c c
53. Dersom du bruker fett på brødet, hvor tykt lag pleier du å 
smøre på? (En kuvertpakke med margarin veier 12 gram) (Sett ett kryss)
Skrapet (3 g) Tynt lag (5 g)
Godt dekket (8 g) Tykt lag (12 g)
54. Hva slags fett bruker du vanligvis på brødet? 
(Sett gjerne flere kryss)
Bruker ikke fett på brødet
Smør
Hard margarin (f.eks. Melange)
Myk margarin (f.eks. Soft, Vita)
Smørblandet margarin (f.eks. Bremyk)
Brelett
Lettmargarin (f.eks. Soft light, Vita Lett)
Margarin med olivenolje (f.eks. Brelett oliven, Soft oliven)
FRUkT og gRøNNSAkER















Epler/pærer ............................ c c c c c c c
Appelsiner o.l. .................... c c c c c c c
Bananer .......................................... c c c c c c c
Annen frukt ........................... c c c c c c c











Kokt ................................................... c c c c c
Most .................................................. c c c c c
Stekt/fritert ............................ c c c c c
57. Hvor ofte spiser du ulike typer grønnsaker?  















Gulrøtter .......................................... c c c c c c c
Kål .............................................................. c c c c c c c
Kålrot ..................................................... c c c c c c c















Blandet salat ............................. c c c c c c c
Tomat.................................................... c c c c c c c
Grønnsakblanding .......... c c c c c c c
Løk ............................................................. c c c c c c c
Bønner ................................................ c c c c c c c
Erter......................................................... c c c c c c c
Andre grønnsaker ............ c c c c c c c
58. For de grønnsakene du spiser, kryss av for hvor mye du 
spiser hver gang: (Sett ett kryss for hver sort)
Gulrøtter ....................................... c 1/2 stk. c 1 stk. c 1 1/2 stk. c 2+ stk.
Potet .................................................... c 1-2 stk. c 3-4 stk. c 5-6 stk. c 7+ stk.
Kål ........................................................... c 1/2 dl c 1 dl c 1 1/2 dl c 2+ dl








Blandet salat .......................... c 1 dl c 2 dl c 3 dl c 4+ dl
Tomat................................................. c 1/4 stk. c 1/2 stk. c 1 stk. c 2+ stk.
Grønnsakblanding .......... c 1/2 dl c 1 dl c 2 dl c 3+ dl
Bønner ............................................. c 1–2 ss c 3–4 ss c 5–6 ss c 7+ ss
Erter...................................................... c 1–2 ss c 3–4 ss c 5–6 ss c 7+ ss
RIS, SpAghETTI, gRøT, SUppE
59. Hvor ofte bruker du ris og spaghetti/makaroni?  











Ris .................................................................................................. c c c c c
Spaghetti, makaroni, nudler ............... c c c c c
60. Hvor ofte spiser du grøt? (Sett ett kryss pr. linje)
aldri/
sjelden










Risengrynsgrøt ....................................... c c c c c c
Annen grøt (havre o.l.) ....................... c c c c c c











Som hovedrett ............................................................... c c c c c
Som forrett, lunsj eller kveldsmat ... c c c c c
FISk
62. Vi vil gjerne vite hvor ofte du pleier å spise fisk, og ber 
deg fylle ut spørsmålene om fiskeforbruk så godt du kan. 
Tilgangen på fisk kan variere gjennom året. Vær vennlig å 




hele året vinter vår sommer høst
Torsk, sei, hyse, lyr ............ c c c c c c
Steinbit, flyndre, uer .... c c c c c c
Laks, sjøørret............................. c c c c c c




hele året vinter vår sommer høst
Makrell .................................................. c c c c c c
Sild ............................................................ c c c c c c
Ferskvannsfisk (abbor, 
gjedde, harr, røye, sik, ørret) .. c c c c c c
Annen fisk ...................................... c c c c c c
63. Med tanke på de periodene av året der du spiser fisk, hvor 











Kokt torsk, sei, hyse, lyr ...................... c c c c c
Stekt torsk, sei, hyse, lyr ...................... c c c c c
Steinbit, flyndre, uer ................................ c c c c c
Laks, sjøørret........................................................ c c c c c
Kveite ............................................................................... c c c c c
Makrell ........................................................................... c c c c c
Sild ....................................................................................... c c c c c
Ferskvannsfisk  
(abbor, gjedde, harr, røye, sik, ørret) ......... c c c c c
Annen fisk ................................................................ c c c c c
64. Dersom du spiser fisk, hvor mye spiser du vanligvis  
hver gang? (1 skive/stykke = 150 gram)
Kokt fisk (skive) ............................................ c 1 c 1 ½ c 2 c 3+
Stekt fisk (stykke) ....................................... c 1 c 1 ½ c 2 c 3+
65. Hvor mange ganger pr. år spiser du fiskeinnmat? 
(Sett ett kryss pr. linje)
0 1–3 4–6 7–9 10+
Rogn ........................................................................... c c c c c
Fiskelever ............................................................... c c c c c
66. Dersom du spiser fiskelever, hvor mange spise skjeer pleier 
du å spise hver gang? (Sett ett kryss)
c 1 c 2 c 3–4 c 5–6 c 7+











Fiskekaker/-pudding/-boller ......... c c c c c
Plukkfisk/fiskegrateng ............................... c c c c c
Frityrfisk/fiskepinner .................................. c c c c c
Andre fiskeretter .............................................. c c c c c
68. Hvor stor mengde pleier du vanligvis å spise av de ulike 
rettene? (Sett ett kryss pr. linje)
Fiskekaker/pudding/boller 
(stk.) (2 fiskeboller=1 fiskekake).................... c 1 c 2 c 3 c 4+
Plukkfisk, fiskegrateng (dl) .............. c 1–2 c 3–4 c 5+
Frityrfisk, fiskepinner (stk.) ................ c 1–2 c 3–4 c 5–6 c 7+
I tillegg til informasjon om fiskeforbruk er det viktig å få kartlagt 
hvilket tilbehør som blir servert til fisk. 
69. Hvor ofte bruker du følgende til fisk?
aldri/
sjelden








Smeltet/fast smør ........................................... c c c c c
Smeltet/fast margarin ............................... c c c c c
Seterrømme (35%) ............................................ c c c c c
Lettrømme (20%) ................................................ c c c c c
Saus med fett (hvit/brun) ........................... c c c c c
Saus uten fett (hvit/brun) .......................... c c c c c
70. For de ulike typene tilbehør du bruker til fisk,  
vær vennlig å kryss av for hvor mye du vanligvis pleier å spise: 
Smeltet/fast smør (ss) ................ c ½ c 1 c 2 c 3 c 4+
Smeltet/fast margarin (ss)............ c ½ c 1 c 2 c 3 c 4+
Seterrømme (ss) ................................. c ½ c 1 c 2 c 3 c 4+
Lettrømme (ss) ...................................... c ½ c 1 c 2 c 3 c 4+
Saus med fett (dl) ............................. c ¼ c ½ c ¾ c 1 c 2+
Saus uten fett (dl) ............................. c ¼ c ½ c ¾ c 1 c 2+
71. Hvor ofte spiser du skalldyr? (f.eks. reker, krabbe og skjell)  
(Sett ett kryss)
c Aldri/sjelden c 1 pr. mnd.
c 2–3 pr. mnd. c 1+ pr. uke
72. Hvor mange måseegg eller egg fra annen sjøfugl spiser du 
i året? (Sett ett kryss)
Aldri 1-3 4-6 7-9 10-15 16+
73. Hvor ofte har du spist ferskvannsfisk? (abbor, gjedde, harr, røye, 













Barndom............................................... c c c c c c
Ungdom 13-19 år ................... c c c c c c
Voksen (før siste året) ...... c c c c c c
kjøTT
74. Hvor ofte spiser du følgende kjøttretter?  













Reinkjøtt .................................. c c c c c c
Elgkjøtt ........................................ c c c c c c
75. Hvor ofte spiser du følgende kjøtt- og fjærkreretter?  











Steik (okse, svin, får)................................... c c c c c
Koteletter (okse, svin, får) ................... c c c c c
Biff (okse, svin, får) ........................................ c c c c c
Kjøttkaker, karbonader .............. c c c c c
Pølser ...................................................................... c c c c c
Rype, annen viltfugl .............................. c c c c c
Gryterett, lapskaus ............................ c c c c c











Kylling med skinn ............................... c c c c c
Kylling uten skinn ............................... c c c c c
Bacon, flesk ................................................... c c c c c
Andre kjøttretter .................................. c c c c c
Blodmat (får, storfe, rein, elg) ......... c c c c c
76. Dersom du spiser følgende retter, oppgi mengden  
du vanligvis spiser: (Sett ett kryss pr. linje)
Steik (skiver) ........................................... c 1 c 2 c 3 c 4 c 5+
Koteletter(stk.) ....................................... c ½ c 1 c 1½ c 2+
Kjøttkaker,  
karbonader (stk.) .......................... c 1 c 2 c 3 c 4+
Pølser (stk. à 150g) .......................... c ½ c 1 c 1½ c 2+
Gryterett, lapskaus (dl) .......... c 1–2 c 3 c 4 c 5+
Pizza m/kjøtt  
(stykke à 100 g) ........................................ c 1 c 2 c 3 c 4+
77. Hvilke sauser bruker du til kjøttretter og pastaretter?  
(Sett ett kryss pr. linje)
aldri/
sjelden








Brun saus .................................................................. c c c c c
Sjysaus .............................................................................. c c c c c
Tomatsaus ............................................................... c c c c c
Saus med fløte/rømme...................... c c c c c
78. Hvor mye bruker du vanligvis av disse sausene?
Brun saus (dl) .............................................. c ¼ c ½ c ¾ c 1 c 2+
Sjysaus (dl) .............................................................. c ¼ c ½ c ¾ c 1 c 2+
Tomatsaus (dl) .......................................... c ¼ c ½ c ¾ c 1 c 2+
Saus med fløte/rømme (dl) ....... c ¼ c ½ c ¾ c 1 c 2+
ANDRE mATvARER
79. Hvor mange egg spiser du vanligvis i løpet av en uke?  
(stekte, kokte, eggerøre, omelett) (Sett ett kryss)
c 0 c 1 c 2 c 3–4 c 5–7 c 8-14 c 15+
80. Hvor ofte spiser du iskrem? (til dessert, Krone-is osv.) 












Om sommeren ...................................................... c c c c c
Resten av året ............................................................ c c c c c
81. Hvor mye is spiser du vanligvis hver gang?  
(Sett ett kryss)
c 1 dl c 2 dl c 3 dl c 4+ dl
82. Hvor ofte spiser du bakevarer som boller, kaker,  













Gjærbakst (boller o.l.) .................... c c c c c c
Wienerbrød, kringle ................ c c c c c c













Pannekaker ............................................. c c c c c c
Vafler ................................................................... c c c c c c
Småkaker, kjeks ............................... c c c c c c
Lefser, lomper ...................................... c c c c c c













Pudding (f.eks. sjokolade/ 
karamell) ........................................................ c c c c c c
Riskrem, fromasj ......................... c c c c c c
Kompott, fruktgrøt, 
hermetisk frukt ............................... c c c c c c
Jordbær (friske, frosne) ................ c c c c c c
Andre bær (friske, frosne) ....... c c c c c c













Mørk sjokolade ................................ c c c c c c
Lys sjokolade ....................................... c c c c c c
85. Dersom du spiser sjokolade, hvor mye pleier du vanligvis å 
spise hver gang? Tenk deg størrelsen på en Kvikk-Lunsj sjokolade, og oppgi 
hvor mye du spiser i forhold til den.
c ¼ c ½ c ¾ c 1 c 1½ c 2+













c c c c c c













Potetchips .................................................. c c c c c c
Peanøtter ..................................................... c c c c c c
Andre nøtter .......................................... c c c c c c
Annen snacks ....................................... c c c c c c
TRAN og FISkEoLjEkApSLER
88. Bruker du tran (flytende)?  .................................................... Ja Nei









Om vinteren .............................................................. c c c c c
Resten av året ......................................................... c c c c c
90. Hvor mye tran pleier du å ta hver gang?
c 1 ts c ½ ss c 1+ss
91. Bruker du tranpiller/fiskeoljekapsler?  ........... Ja Nei
92. Hvis ja, hvor ofte tar du tranpiller/fiskeoljekapsler? 









Om vinteren .............................................................. c c c c c
Resten av året ......................................................... c c c c c
93. Hvilken type tranpiller/fiskeoljekapsler bruker du vanligvis, 
og hvor mange pleier du å ta hver gang? 
Navn på produkt: __________________________________________________________________
Antall: c 1 c 2 c 3+
Kosttilskudd
94. Bruker du kosttilskudd? 
(vitaminer/mineraler) ............................................................................................... Ja Nei
Alkohol
95. Er du totalavholdskvinne/mann?  ............................ Ja Nei
96. Hvis nei, hvor ofte og hvor mye drakk du i gjennomsnitt 

















Øl/rusbrus (½ l.) .............. c c c c c c c c
Vin (glass) .................................... c c c c c c c c
Brennevin (drink/shot) . c c c c c c c c
Likør/hetvin (glass) .... c c c c c c c c
Tannhelse
97. Sist du gikk til tannlege, gikk du til en tannlege/tannpleier 
i privat praksis eller til en tannlege/tannpleier ansatt i den 
offentlige tannhelsetjenesten? (Sett kryss) 
Tannlege i privat praksis
Tannlegespesialist i privat praksis
Tannpleier i privat praksis
Tannlege ansatt på offentlig tannklinikk
Tannlegespesialist ansatt på offentlig tannklinikk
Tannpleier ansatt på offentlig tannklinikk
Tannlege i utlandet
98. Når var du sist hos tannlege/tannpleier? (Sett ett kryss) 
Mindre enn ett år siden 1-2 år siden
3-5 år siden Mer enn 5 år siden
99. Hvis det er mer enn 2 år siden, hva er da grunnen? 
(Sett ett kryss) 
Jeg har ikke blitt innkalt Det er lang ventetid hos tannlegen
Jeg har ikke hatt tid Økonomiske årsaker
Jeg har ikke hatt behov for 
tannbehandling
Jeg er redd eller engstelig 
for å gå til tannlege
Andre årsaker:
100. Hvor mye har du betalt i alt for din egen tannbehandling 
(tannlege, spesialist og tannpleier) de siste 12 månedene?  
(Sett ett kryss)
Ingenting (har ikke vært 
hos tannlegen)
Ingenting (har fått 
kostnadene dekket)
Mindre enn 1000 kroner 1000-5000 kroner
5001-10.000 kroner 10.001-20.000 kroner
Over 20.000 kroner
101. Sett kryss for de to viktigste forhold med tennene for deg 
personlig?
At tennene er pene når jeg snakker og smiler ........................
At tennene er smertefrie .............................................................................................
At jeg kan tygge uten problemer .................................................................
At min pust er god ................................................................................................................
At jeg har mine tenner resten av livet ...................................................
102. Hvordan vurderer du tannhelsen din? (Sett ett kryss)
 Dårlig  Ikke helt god  God  Svært god
103. Har du tannprotese/gebiss/tannbro? .............. Ja Nei
Soling
104. Har du vært i syden eller på annen 
solferie i løpet av den siste måneden?  ..................... Ja Nei
105. Hvor mye har du vært ute i dagslys i 
løpet av de siste 7 dagene? ............................................................ timer
106. Har du vært i solarium i løpet av den siste måneden? 
Nei 1 - 2 ganger 3+ ganger
Hudpleiemidler
107. Hvor ofte (antall ganger) bruker du følgende 















Ansiktskrem ................................. c c c c c c c
Håndkrem ....................................... c c c c c c c
Bodylotion ...................................... c c c c c c c
Parfyme/aftershave ......... c c c c c c c
Deodorant ........................................ c c c c c c c
Hårprodukt (utenom 
shampo/ balsam) .............................. c c c c c c c
Egne barn og amming
108. Hvis du er kvinne og har født barn, kan du angi fødselsår  








Barn nr. 1 ............................................................ c
Barn nr. 2 ............................................................... c
Barn nr. 3 ............................................................... c
Barn nr. 4 ............................................................... c
Barn nr. 5 ............................................................... c
Dersom flere barn, skriv på eget ark.
Familie og språkbakgrunn
109. Hvordan var de økonomiske forhold i familien under din 
oppvekst? (Sett ett kryss)
Meget gode Gode Vanskelige
Meget 
vanskelige
I Nord-Norge bor det folk med ulik etnisk bakgrunn. Det vil si at 
de snakker ulike språk og har forskjellige kulturer. Eksempler på 
etnisk bakgrunn, eller etnisk gruppe er norsk, samisk og kvensk.
110. Hvilket hjemmespråk har/hadde du, dine foreldre og 
besteforeldre? (Sett ett eller flere kryss pr. linje)








111. Hva er din, din fars og din mors etniske bakgrunn? 
(Sett ett eller flere kryss pr. linje)
Norsk Samisk Kvensk Annet, beskriv:
Min etniske bakgrunn er ...................
Min fars etniske bakgrunn er .....
Min mors etniske bakgrunn er 
112. Hva regner du deg selv som? (Sett ett eller flere kryss)
Norsk Samisk Kvensk Annet, beskriv:
Kroppsfigur
1 2 3 4 5 6
1 2 3 4 5 6
1 2 3 4 5 6
1 2 3 4 5 6
1 2 3 4 5 6
1 2 3 4 5 6
Figur nr.
113. Hvilken figur ligner mest på deg? ..................................................
Figur nr. mann Figur nr. kvinne
114. Hvilken figur tilsvarer en kropp som 
du synes ser mest sunn ut? ..............................................
115. Hvilken figur er den første i 
stigende rekkefølge som  
du oppfatter som tykk? ..........................................................
116. Hvilken figur er den første i 
synkende rekkefølge som  
du oppfatter som tynn? .........................................................
117. Hva oppfatter du deg selv som? (Sett ett kryss)
Alt for tykk For tykk Passe For tynn Alt for tynn
118. Har du forsøkt å gå ned i vekt/slanket 
deg de siste 6 måneder? ..................................................................... Ja Nei
119. Hvis ja, hvor mange kilo har du gått ned 
de siste 6 måneder? ..................................................................................... Kg
120. Hvilke metoder brukte du for å gå ned?  
(Sett ett eller flere kryss)
Spiste mindre Spiste sunnere Andre kostendringer
Mosjon
Slankemidler  
ordinert fra lege Slankepulver
Annet, beskriv:
Andre ubehag
121. Under finner du en oppstilling av plager som man av og til 
har. Les nøye gjennom dem, en for en, og angi deretter hvor 
mye hvert enkelt problem har plaget deg eller vært til besvær 










Stadig redd eller engstelig ...................................
Følelse av håpløshet med tanke på 
fremtiden ..........................................................................................
Mye bekymring eller urolig .................................
Nedtrykt, tungsindig ......................................................
Søvn
Vi vil gjerne stille deg noen spørsmål om dine søvnvaner. Vær 
oppmerksom på at klokkeslettene må angis i 24 t., det vil si at 
11:00, er elleve på formiddagen, og 23:00, er elleve om kvelden.
122. Har du hatt skiftarbeid (natt- og eller 
kveldsarbeid) de siste tre månedene? ........................ Ja Nei
123. Hvor mange dager i uken har du ikke anledning til å velge 
fritt når du vil sove og når du vil stå opp? (Kan f.eks. gjelde for dager 
hvor du skal på arbeid, skole etc.) (Sett ett kryss)
0 1 2 3 4 5 6 7
c c c c c c c c
124. På dager jeg ikke har anledning til å velge fritt når jeg vil 
sove/stå opp:
Time Minutt
Da går jeg til sengs klokken .........................................................................
Jeg gjør meg klar til å sovne klokken .............................................
Antall minutter det vanligvis tar før jeg sovner helt ..
Jeg våkner klokken...................................................................................................
Jeg våkner ved hjelp av:
Vekkerklokke
Ytre påvirkning 
(f.eks. støy fra 
familie eller andre)
Av meg selv
Antall minutter det tar før jeg vanligvis står opp ...................
Sover du i tillegg på slike dager også på 
andre tider av døgnet? (f.eks. middagshvil) .................... Ja Nei
Time Minutt
Når (kl.) skjer det vanligvis .............................................................................
Antall minutter du da sover .........................................................................
125. Når jeg fritt kan sove/stå opp:
Time Minutt
Da går jeg til sengs klokken ....................................................................
Jeg gjør meg klar til å sovne klokken ........................................
Antall minutter det vanligvis tar før jeg  
sovner helt ......................................................................................................................
Jeg våkner klokken..............................................................................................
Jeg våkner ved hjelp av:
Vekkerklokke Ytre påvirkning (f.eks. støy fra familie eller andre) Av meg selv
Antall minutter det tar før jeg vanligvis står opp ...................
Sover du i tillegg på slike dager også på 
andre tider av døgnet? (f.eks. middagshvil) ........................ Ja Nei





























































1.  I hvilket år er du født? ...........................................................
2. Er du? .....................................................................................................
Kvinne Mann
3. Hva er din sivilstatus?
Gift Samboer Skilt
Ugift Enke/enkemann
4. Hvor mange års skolegang har du 
gjennom ført? (Ta med alle år du har gått på skole 
eller studert).......................................................................................................................................
Antall år
5. Hvis du er kvinne: Hvor mange barn har 
du født? .............................................................................................................................
Antall




7. Hvordan er helsen din? (Sett ett kryss)
Dårlig God
Ikke helt god Svært god
8. Hvordan vurderer du tannhelsen din? (Sett ett kryss)
Dårlig God
Ikke helt god Svært god
9. Har du tannprotese/gebiss/
tannbro?  ................................................................................................................ Ja Nei
10. Når var du sist hos tannlege eller tannpleier?
Mindre enn ett år siden 1–2 år siden
3–5 år siden Mer enn 5 år siden
11. Hvor fornøyd er du med tannhelsetjenesten i din 








12. Har du eller har du hatt høyt 
blodtrykk?  ........................................................................................................... Ja Nei
Alder
13. Hvis ja, hvor gammel var du da du fikk 
høyt blodtrykk? ........................................................................................................
14. Bruker du medisin 




15. Hvis du bruker eller tidligere har  
brukt blodtrykksmedisin, omtrent hvor  
gammel var du første gang du begynte med 
slik medisin? ....................................................................................................................
Alder
16. Har du hatt hjerteinfarkt? 
Nei, aldri 1 gang 2 ganger 3 eller flere
Alder
17. Hvis ja, hvor gammel var du første gang 
du fikk hjerteinfarkt? .....................................................................................
18. Har du angina pectoris 
(hjertekrampe)?  ................................................................................... Ja Nei
19. Hvis ja, hvor ofte har du merket slike smerter i 
løpet av den siste måneden?  ..............................................................................................





7 eller flere 
ganger pr. uke
Alder
20. Hvor gammel var du første gang du fikk 
angina pectoris? ......................................................................................................
21. Har du blitt hjerteoperert 
(bypass)?  ................................................................................................................ Ja Nei
22. Har du blitt blokket/fått innsatt 
stent?  .............................................................................................................................. Ja Nei
23. Har legen sagt at du har 
hjerteflimmer?  ......................................................................................... Ja Nei
Alder
24. Hvor gammel var du første gang du fikk 
hjerteflimmer? ............................................................................................................
Helse - og 
livsstils-
undersøkelse
Vi ber deg fylle ut spørreskjema så nøye som mulig og 
levere det ved oppmøte til den innkalte helseundersøkelsen. 
Skjema skal leses optisk. Vennligst bruk blå eller sort penn. 
Bruk blokkbokstaver. Du kan ikke bruke komma, forhøy for eksempel 0,5 til 1.
Diabetes (sukkersyke) 
25. Har du noen gang fått påvist 
diabetes (for høyt blodsukker)?  ...................... Ja Nei
Dersom nei, gå videre til spørsmål 35.  
26. Dersom ja, hvilken type diabetes har du fått 
påvist? (Sett ett eller flere kryss)
Svangerskapsdiabetes  .............................................................................................................
Diabetes type I  ..........................................................................................................................................
Diabetes type II  ........................................................................................................................................
27. Hvordan ble din diabetes oppdaget? 
Jeg søkte lege pga. symptomer ............................. Ja Nei
Ble oppdaget uten at jeg hadde 
symptomer (legeattest, bedriftskontroll, 
svangerskapskontroll, undersøkelse for annen 
sykdom e.l.) ................................................................................................................... Ja Nei
Alder
28. Hvor gammel var du da din diabetes ble 
oppdaget? ............................................................................................................................................
INSULIN
29. Bruker du insulin 






Dersom du bruker eller har brukt insulin:
Alder
30. Hvor gammel var du da du 
begynte med insulin? ...........................................................
31. Hvor mange ganger pr. dag tar 
du/tok du vanligvis insulin? .................................. ganger
32. Hvor mange enheter insulin tar 
du/tok du vanligvis til sammen pr. 
dag? ................................................................................................................................. enheter(E)
TABLETTER
33. Bruker du tabletter 






Dersom du bruker eller har brukt tabletter:
Alder
34. Hvor gammel var du da du begynte med 
tabletter mot diabetes? ......................................................................................
Andre sykdommer
35. Har du eller har du noen gang hatt?




Kronisk bronkitt, emfysem, 
KOLS.......................................................................................
Multippel sklerose (MS)  ...........
Psoriasis  .......................................................................
Bechterews sykdom  .........................
Smerter
36. Har du smerter nå som har vart i  
tre måneder eller lengre? ................................................ Ja Nei
37. Hvis ja, vennligst angi hvor sterke smerter du har 
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39. Vi ber deg angi din fysiske aktivitet etter en 
skala fra svært lite til svært mye da du var 14 år, 
30 år og i dag. Skalaen nedenfor går fra 1-10. Med 
fysisk aktivitet mener vi både arbeid i hjemmet og i 
yrkeslivet, samt trening og annen fysisk aktivitet som 
turgåing o.l. Sett kryss under det tallet som best angir 
ditt nivå av fysisk aktivitet.
Svært lite Svært mye





40. Er du totalavholdskvinne/mann?  ... Ja Nei
41. Hvis nei, hvor ofte og hvor mye drakk du i 

























(½ l.) ................................... c c c c c c c c
Vin  
(glass) .............................. c c c c c c c c
Brennevin  
(drink/shot) ............... c c c c c c c c
Likør/hetvin 
(glass) .............................. c c c c c c c c
Røykevaner
42. Har du noen gang røykt daglig? ......... Ja Nei
Dersom du aldri har røykt daglig, kan du gå videre 
til spørsmål 47.
43. Røyker du daglig nå? ..................................................... Ja Nei
44. Hvis du har sluttet å røyke daglig, hvor 
gammel var du da du sluttet? ................................................................
Alder
45. Hvor mange år til sammen har du røykt 
daglig? .........................................................................................................................................................
År
46. Hvor mange sigaretter/rulletobakk har 
du i gjennomsnitt røykt daglig i de årene du 
har røkt daglig?......................................................................................................................
Antall
47. Bor du sammen med noen som 
røyker? ........................................................................................................................... Ja Nei
Språk og bruk av tolk
48. Hvilket språk ønsker du først og fremst å snakke 
med helsepersonell på? (Sett ett eller flere kryss)
Norsk Samisk   Annet, beskriv:
49. Hvis du har svart «samisk», men ikke fikk tilbud om 




Ønsker ikke bruke tolk Ikke aktuelt
På sykehus/ hos spesialist
Ja Nei
Ønsker ikke bruke tolk Ikke aktuelt
Familie og språkbakgrunn
50. Hvordan var de økonomiske forhold i familien 
under din oppvekst? (Sett ett kryss)
Meget gode Gode Vanskelige
Meget 
vanskelige
I Nord-Norge bor det folk med ulik etnisk bakgrunn. 
Det vil si at de snakker ulike språk og har forskjellige 
kulturer. Eksempler på etnisk bakgrunn, eller etnisk 
gruppe er norsk, samisk og kvensk.
51. Hvilket hjemmespråk har/hadde du, dine 
foreldre og besteforeldre? (Sett ett eller flere kryss)








52. Hva er din, din fars og din mors etniske 
bakgrunn? (Sett ett eller flere kryss)
Norsk Samisk Kvensk    Annet,beskriv:
Min bakgrunn:...........................
Min fars bakgrunn: ..........
Min mors bakgrunn: ....
53. Hva regner du deg selv som?  
(Sett ett eller flere kryss)
Norsk Samisk Kvensk Annet, beskriv:
Andre sykdommer
35. Har du eller har du noen gang hatt?




Kronisk bronkitt, emfysem, 
KOLS.......................................................................................
Multippel sklerose (MS)  ...........
Psoriasis  .......................................................................
Bechterews sykdom  .........................
Smerter
36. Har du smerter nå som har vart i  
tre måneder eller lengre? ................................................ Ja Nei
37. Hvis ja, vennligst angi hvor sterke smerter du har 
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39. Vi ber deg angi din fysiske aktivitet etter en 
skala fra svært lite til svært mye da du var 14 år, 
30 år og i dag. Skalaen nedenfor går fra 1-10. Med 
fysisk aktivitet mener vi både arbeid i hjemmet og i 
yrkeslivet, samt trening og annen fysisk aktivitet som 
turgåing o.l. Sett kryss under det tallet som best angir 
ditt nivå av fysisk aktivitet.
Svært lite Svært mye




Er faringer og bruk av helsetjenester
54. Den legen du vanligvis bruker er:
Din fastlege Annen lege
55. Hvor lenge har du hatt din nåværende fastlege?
Mindre enn 6 mnd 6 til 11 måneder
12 til 24 mnd Mer enn 2 år
56. Har du i løpet av de siste 12 mnd 
kontaktet fastlegen din for hjelp 
eller råd til deg selv?..................................................................... Ja Nei
Hvis ja, opplevde du at du fikk den hjelpen 
du ba om?
Aldri Av og til Vanligvis Alltid
57. Hvor fornøyd eller misfornøyd er du med 















Ventetid for å få time 
hos fastlege ....................................
Tid hos fastlegen ................
Fastlegens forståelse 




under søkelse og 
behandlingsopplegg .
Totalt sett, hvor 
fornøyd eller 
misfornøyd er 
du med den 
kommunale 
helsetjenesten?........................
De neste spørsmålene omhandler 
spesialisthelsetjenesten.
Med spesialisthelsetjenesten menes det sykehus, 
distriktspsykiatrisk senter (DPS), spesialistlegesenter 
eller enkeltspesialist. 
58. Har du i løpet av de siste 12 måneder vært til 





59. Har du i løpet av de siste 12 måneder vært til 
undersøkelse eller behandling for psykiske plager hos:





60. Dersom du har vært til behandling hos spesialist 
for fysiske eller psykiske plager, svar på følgende 
spørsmål: (Sett ett kryss) 
Svar på en skala fra 0 til 10 (0 = i liten grad 10 = i stor grad)
Fikk du anledning til å fortelle det du følte var 
viktig om din tilstand? 
Ikke 




Snakket legene/behandlerne til deg slik at du 
forstod dem? 
Ikke 




Alt i alt, har du tillit til sykehuset eller spesialisten 
du var hos?
Ikke 




Alt i alt, hvor tilfreds er du med pleien og 
behandlingen du eventuelt fikk?
Ikke 




Takk for at du deltok i undersøkelsen!
